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CHAPTER 1: INTRODUCTION 
‘It must be remembered that there is nothing more difficult to plan, more doubtful of 
success, nor more dangerous to manage than the creation of a new system. For the initiator has the 
enmity of all who would profit by the preservation of the old institutions and merely lukewarm 
defenders of those who would gain by the new ones.’ 
Niccolo Machiavelli (1469 - 1527)  
Healthcare within the past several decades have seen an impetus towards precision 
medicine leading to “dramatic changes in how health care is delivered.” 1   This growth has 
generated an expansive industry that produces genome- and molecular-based laboratory tests, 
reagents and protocols required to detect and treat illnesses.  In the laboratory, these new diagnostic 
methods are referred to as “Laboratory Developed Tests” or LDT.  2 LDT are defined as a sub-set 
of in vitro diagnostics (IVDs) that are “intended for clinical use and designed, manufactured and 
used within a single laboratory”.2   Historically, tests were developed by medical laboratories on a 
small scale, but as the interest in molecular testing expanded, large diagnostic manufacturers also 
began to develop and mass market LDT.2 (3) Governmental public safety agencies became 
interested in the marketing claims stated by these manufactures and the accompanying medical 
outcomes.4  
In 2004, poorly validated research alerted the FDA to a laboratory industry that lacks 
regulatory oversight and structure for design, development and testing of LDT. 56 Historically, 
laboratories were under enforcement discretion by the Food and Drug administration and have 
adverted the approval process as required for laboratory test kit manufactures under the medical 
device act F, D & C and 21 CFR 820.4   The test registration and regulatory approval process is 
difficult to manage and according to the Centers for Medicare & Medicaid Services (CMS), there 
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are approximately 254,000 laboratory entities in the U.S. with 335,700 medical technologists and 
technicians. In addition, the expansion of genetic testing also contributes to the complexity and 
introduces a significant amount of test variation to field of LDT. 11, 61 
 In addition, a significant gap exists between the Clinical Laboratory Improvement Act (CLIA) 
established for laboratory accreditation and FDA regulations. 
To address this issue, the FDA proposed a rigorous approval process to reduce or eliminate 
the potential for error in healthcare like that required for manufacturers of medical device in a draft 
guidance entitled Framework for Regulatory Oversight of Laboratory Developed Tests.3   In this 
draft guidance, the FDA presents the agency approach for LDT oversight as a public health risk”.  
2, 3 In addition, the FDA proposes a process for risk classification, time frames for LDT 
registration, a formalized design control structure and a phased implementation plan for a Quality 
System Regulation (QSR) for laboratories that register LDT for high risk or moderate risk 
classifications.2  Laboratories developing rare LDTs are exempt from the requirements described 
in the proposal because as described,  the outcome of an incorrect result or incorrect interpretation 
is unlikely to affect morbidity, mortality or the safety of patients. 3 
This QSR management structure is presented from a medical device perspective and 
encompasses a structure consisting of management responsibilities, procedures, processes, and 
resources to ensure patient safety.  Laboratories disputed the FDA oversight and QSR structure 
comprised of medical device requirements and challenged the applicability to diagnostic testing. 
42   Many laboratories may lack the resources or regulatory understanding to develop a quality 
system program that meets FDA specifications.44  
 The draft guidance resulted in significant resistance from the laboratory community and 
following a period of public comment, the Agency announced, in a Discussion Paper dated January 
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13, 2017, that they were considering possible alternatives to the original framework.  6,7 The FDA 
continues the proposition for regulatory requirements from the 2014 draft guidance and 
emphasizes the adoption of a (QSR) for the development of LDT that include design controls, 
acceptance criteria and corrective and preventive action procedures as referred to in the 2017 
Discussion Paper. 6, Moreover, the laboratories continue to struggle to understand the implications 
of this additional regulatory oversight, and their responsibility to comply in the event the draft 
guidance becomes policy. 
Motivation for this Research 
The motivation of this study is to understand regulatory requirements, laboratory 
constraints and necessary factors to design, develop and implement a regulatory quality 
management system for laboratories that perform high risk and moderate risk LDT.  In the absence 
of a required laboratory accreditation quality management system standard, I will explore 
requirements as mandated for the medical device industry and understand how these principles 
especially product development methodology of design control may align and be applicable to 
laboratory testing. 14  
Through this study I will investigate, develop, design and address management practices 
that will best support unique product variation, accuracy of results particularly important for 
addressing the patient safety concerns of the FDA and speed of processing within a high -volume 
routine automated laboratory. The framework will incorporate process standardization to support 
manufacturing requirements of product, people and service. I will explore the applicability of the 
agile product development technique to a laboratory environment that will assist laboratories 
comply with all pertinent regulations and expedite test development. 47  
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The problem is as follows: If the FDA mandates an adoption of a Quality System Regulation for 
the process of Laboratory Developed Tests, how will laboratories design, adopt and implement a 
quality management system that commit to this requirement. 
Research Goals 
The inspiration to conduct this research is expressed through my lifelong commitment and 
contribution to positively affect healthcare. My career began in a recovery facility where I cared 
for the sick, elderly and disabled and it was there that I developed a concern for the welfare of 
people who were unable to care for themselves.  It was through this experience that I discovered 
my passion for patient safety and consequently has persisted as the focal point of my work. I spent 
many years in laboratories and later as a consultant that assisted leadership achieve increase levels 
of quality through waste elimination and process standardization. This research study to explore 
the perceived apprehension associated with laboratory testing, the associated literature review and 
the call for action by governmental agencies opened my eyes to a reality of an industry that lacks 
regulatory controls and oversight for diagnostic tests, a service, that clinicians and patients depend 
for treatment decisions.  
From a practical perspective, the proposed FDA recommendations, if implemented 
effectively, could transform healthcare on a global level and set the world standard for global 
laboratory quality. 
The scholarly goals of the proposed changes as recommended by the FDA can be described 
as an impetus to change within a historically stable regulatory laboratory environment. These 
recommendations by the FDA may guide the current state of laboratories into futuristic change.  
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Scope of this Research 
The scope of this research is limited to laboratories actively developing in house high risk 
and moderate risk LDTs within a system that has yet to understand, define and implement 
regulatory processes that align with pertinent regulations for patient safety as proposed by the 
FDA. The development of rare LDTs is out of the scope of this research due to the exemption 
status described in the 2014 draft guidance for LDT. The outcome of an incorrect result for a rare 
LDT is unlikely to affect morbidity, mortality or the safety of patients. 3 
Research Questions  
The following research questions have been proposed:  
1. Can laboratories operationalize a quality management framework that will meet FDA 
requirements?  
2. Will an adoption of a quality system framework provide the manufacturing foundation that 
will adhere to 21 CFR 820 Design Controls?  
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CHAPTER 2. LITERATURE REVIEW 
This literature review will outline the history of LDT, regulatory involvement and the 
current condition within the scientific community regarding laboratory-developed tests. 
The Laboratory Improvement Amendment Act (CLIA) 1988 was developed and enforced under 
the direction of the Centers of Medicare and Medicaid Services (CMS) and was passed to assure 
the safety of the American healthcare system in general and specifically to oversee laboratory 
testing.  The objective of this legislation is to ensure the integrity of laboratory testing and results. 
“12   
Although CMS has oversight for laboratory accreditation, the Governmental Accounting 
Office (GAO), conducted a study for commercially manufactured home genetic testing kits 
marketed and sold to consumers that were noted to provide little medically useful information and 
worst, test results “were misleading and of little or no practical use”. 4  To circumvent these issues, 
two bills were introduced to allow the FDA to hold LDT manufactures to the same standard as 
medical device firms. The bills were not passed and although their actions have become a source 
of controversy, the FDA preemptively assumed oversight over the manufacture and regulation of 
all LDT.4   
Since the bills were introduced to congress, the FDA has identified problems with several 
high-risk LDT that includes: “claims that are not adequately supported with evidence; lack of 
appropriate controls yielding erroneous results; and falsification of data”.  5   The FDA is concerned 
for patient safety and the potential outcomes of unregulated tests for a “health condition that could 
result in illness or death.” 5  
Although, the FDA was given oversight and authority over diagnostic testing 17  and regulate 
manufacturers and devices under the Federal Food, Drug, and Cosmetic Act (FFDCA), CLIA 
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retains oversight to ensure clinical laboratories operate as described in federal regulation 21 CFR 
493.  
 Healthcare systems aboard are vastly different. As early as 1990, the United Kingdom 
instituted regulations that consisted of the establishment of clinical governance to regulate quality 
systems in healthcare and to hold each organization liable for outcomes.  As a result, the goal to 
eliminate poor quality for the best interest of the patient is demonstrated through continuous 
improvement, risk management and the establishment of processes to minimize errors. In the NHS, 
all leaders are responsible for quality outcomes by managing adverse events, customer complaints, 
and by ensuring that policies and procedures are implemented for all elements of the system 62 
Concerns from Professional Societies 
Unlike the NHS, many organizations have objected to the FDA’s oversight of LDT, 
including the American Hospital Association, the American Cancer Institute (ACI), and the 
American Clinical Laboratory Association (CLA). The American Medical Association has stated 
“the FDA proposal will add an additional layer of regulatory requirements which may result in 
patients losing access to timely lifesaving diagnostic services and hinder advancements in the 
practice of medicine.” 21  
The CLA has argued, “The FDA requirements would stifle laboratory innovation and retard patient 
access to critical diagnostics.” 3  Moreover, the academic laboratories if held to the 21 CFR 820 
standards may be required to perform clinical trials for each new genetic test developed. This 
process would require additional resources and as explained by Evans, (2015) “laboratories have 
insufficient resources to meet the proposed requirements and would essentially be precluded from 
developing or even improving tests in response to patient needs, clinician demands and changing 
technology.” 10 The perceived outcome of an innovation may influence professional groups to 
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abandon processes advantageous to patient safety and Sanson-Fischer, (2004) explains “If a 
proposed change alters the balance of power between or within professional groups in a “negative” 
way, the innovation may not be implemented.” 22 To eliminate complexity and shorten the approval 
time for new test development, the FDA is currently seeking the advice of a steering committee 
that consists of multiple organizations and professional agencies to agree on a path for the best 
interest of patient safety. 22  The FDA proposed framework lacks formal structure, tools 
standardization and defined rules for use.  
Process Standardization 
A standardized harmonious approach or mandate for quality and standardization has not 
been defined for US laboratories. Outside of the laboratory, many industries have adopted practices 
aligned with quality standardization, however, successful implementation is based on the support 
of leaders to own and drive an organic, directed initiatives with tasks and activities applied to local 
specific organizational processes. As W. Edwards Deming secretary stated in a 1989 video, 
“American managers would like to choose and implement quality from a Chinese menu, but there 
is no instant pudding. Quality doesn't work that way.” 23  
Total Quality Management  
The standardization of organic processes can be found described in a 20-year-old 
interpretation of a Deming management philosophy, known as Total Quality Management (TQM).  
Continuous improvement, employee empowerment and standardization were at the heart of the 
successful application of Deming management principles as applied to the Toyota Motor Corp.  
This success story was described by academic scholars at major US institutions such as: MIT 
(Womack,1990), Harvard (Spear and Bowen 1999) and University of Michigan (Liker, 2004). 30, 
31, 33  Toyota’s brand of TQM came to be labeled as ‘Lean’ referring to the bufferless production 
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system by a graduate student of Womack named John Krajcik (Krafcik 1988) former CEO of 
Hyundai America.  
Outside of Toyota, one of the best examples of an TQM initiative in healthcare was of a 
new hospital CEO, Charles Evans of Memorial Hospital, Jacksonville, FL in 1991 (Case 1995) 
touting TQM as key to culture change. 30  However, no subsequent publications described or were 
issued by this institution. In fact, search of this hospital’s current website 22 years later shows 
neither trace of that CEO nor any mention of a culture of continuous improvement, TQM, Lean or 
Deming.  This is typical of the archeology of TQM and is described by a (quotation-George 
Santayana) “Those who cannot remember the past are condemned to repeat it.”  
Continuous improvement efforts with new names continuously emerge as the flavor of the 
year, however, have organizations altered their management approach to change?  
As referenced by Gatchalian, 1997 the most common reasons for failure in creating successful 
cultures of continuous improvement, were associated with problems of sustainability of leadership 
and purpose, absence of strategic communications and teamwork for quality improvement, and 
lack of total commitment to the Deming management /TQM philosophy and practice. 34   These in 
turn were derived from poor understanding of the Deming philosophy by upper management and 
a general lack of employee opportunities to relate training activities with company mission/vision 
or directions. 35 Implementation of TQM follows an historic repetition of similar practices per 
Naslund, (2008). 36   Organizations continue to re–invent the wheel, but never pause to self-reflect 
on the lessons of the past.  A description of this similar pattern has been described as the seven-
stage life cycle of a fad for Total Quality Management and early phases of the life cycle cited by 
Naslund (2008) in relation to the current enthusiasm for Lean management in healthcare.   36  
The life cycle is described as follows: An academic article is written on a new discovery or theory; 
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1. The study is discussed, summarized, and repeated; 
2. The concept is popularized in a best- selling book; 
3. Management consultants carry new techniques to their client base; 
4. Managers embrace the fad and champion the concept; 
5. Time passes, enthusiasm dims, and doubts and cynicism arise; and 
6. New discovers occur and consultant interest turns elsewhere.  
TQM did not sustain and can be seen in the trend of publications, indicating original initiatives or 
the buzz, peaking in the early 1990s and then trailing off.   
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CHAPTER 3. FACING THE INEVITABLE: BEING PREPARED FOR REGULATORY 
REQUIREMENTS FOR LABORATORY DEVELOPED TESTS 
 
Overview 
This chapter address an application of a standard manufacturing approach to the laboratory 
is described through the application of a research design for development of a Quality Management 
System titled Facing the Inevitable: Being Prepared for Regulatory Requirements for Laboratory 
Developed Tests.  The objective was a call for action to educate the laboratory community by 
introducing terms, definitions and regulatory requirements. We discuss how these requirements 
may be applicable from the medical device industry to laboratory medicine.  We performed nine 
interviews with laboratory professionals and as a result of the feedback developed and tested 
strategic factors by use of a survey that would comprise a quality management system framework 
with product development methodology to incorporate design control. This manuscript was sent 
for publication in the American Journal of Clinical Pathologists.  
Introduction   
Contemporary technological advances in laboratory medicine have led to a category of 
laboratory diagnostics known as Laboratory Developed Tests (LDTs). LDTs are defined as a 
subset of in vitro diagnostics (IVDs) that are “intended for clinical use and designed, manufactured 
and used within a single laboratory”.2  In recent years, the Food and Drug Administration (FDA) 
identified problems with several high-risk LDT and has cited concerns that “patients could initiate 
unnecessary treatment, delay or forego treatment altogether”.2  In addition to the FDA, other 
governmental agencies, and private organizations have challenged the validity, accuracy, 
oversight, and safety of in LDTs. The FDA has now proposed requiring “all in-vitro diagnostic 
(IVD) tests intended for use in drug or biologic therapeutic decision-making be held to the same 
scientific and regulatory standard” as medical device firms.2  
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Since medical device development is held to a stringent and lengthy regulatory approval 
process, there is significant apprehension regarding the potential for undue delays in test 
development and patient access should LDT be held to the same standard. Unlike the medical 
device industry, which is subject to the requirements of the FDA, clinical laboratories are under 
the jurisdiction of the Centers for Medicare and Medicaid (CMS).11  The FDA has proposed that 
laboratories adopt a formal risk-based classification and approval process, Quality System 
Regulation (QSR), and a formalized design control structure, as described in their 2014 draft 
guidance entitled Framework for Regulatory Oversight of Laboratory Developed Tests.2  In this 
draft, the FDA proposes directives that are currently not mandated by CLIA or any other regulatory 
agency regarding laboratory oversight.  Following a period of public comment, the Agency 
announced, in a Discussion Paper dated January 13, 2017, that they were considering possible 
alternatives to the original framework proposal. 6  Laboratories continue to struggle to understand 
the implications of this additional regulatory oversight and their responsibility to comply in the 
event the draft guidance becomes policy. Additionally, for those laboratories licensed by the New 
York State Department of Health (NYSDOH), the Wadsworth Center’s Clinical Laboratory 
Evaluations Program (CLEP) has recently adopted a three-tiered, risk-based review and approval 
policy for all LDT submissions, effective November 14, 2016. Risk stratification is based upon an 
algorithm guided by three criteria: 1) well-established methodology, 2) key determinant of care 
assessment, and 3) the potential for patient impact.7 It is interesting to note that in their recent 
Discussion Paper the FDA suggests the possible use of third-party collaborators, including the 
NYSDOH CLEP for review of LDTs.  The Agency indicates that they are “exploring accepting 
NYSDOH review in lieu of its own”.6  
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Motivation for the Research 
The motivation for this research is to educate the laboratory community pertinent to LDTs 
by introducing terms, definitions, regulatory requirements and discuss the QSR as proposed by the 
FDA. We compare the requirements of the 21 CFR 820 to the recommended Clinical Laboratory 
Standards Institute (CLSI) 12 Quality System Essentials (QSE) for laboratories to understand how 
these principles may be incorporated and translated into laboratory processes that align and support 
the QSR. We also explore “design control” and discuss how these requirements for the medical 
device industry may be applicable to laboratory testing. We conducted interviews with laboratory 
professionals to gain an understanding of their concerns regarding the FDA draft guidance and 
translated that feedback into operational factors relevant for the development of a robust quality 
management system.  Finally, we tested the factors for functionality, agility and usefulness through 
a survey and propose the design of a framework to assist laboratories prepare in the event the 2014 
draft guidance becomes a policy. 
Contribution: This paper contributes to the discussion about LDT by serving as a proactive call 
for action by educating laboratory professionals and providing the impetus to move from a wait-
and-see approach to insight, knowledge and clarity that encompasses the many facets of LDT.  We 
construct a means to collect substantiated data regarding the needs and gaps in laboratories and 
propose translation of those objectives into a vocabulary familiar to laboratorians. Finally, we 
translate and validate functionality and usefulness of strategic factors for design of a robust 
regulatory QMS by voice of customer. 
Background 
The literature provides a rich background regarding the history of laboratory developed 
tests. The FDA, other governmental agencies and private firms have challenged the validity, 
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accuracy, oversight and safety of laboratory testing.  In 2008, Genentech, a private medical device 
manufacturer firm of oncologic pharmaceuticals and laboratory reagents, disputed laboratories or 
other companies selling LDTs or making statements without sufficient scientific evidence to 
support such claims. 8  Genentech petitioned the FDA to “require all in-vitro diagnostic (IVD) tests 
intended for use in drug or biologic therapeutic decision-making be held to the same “scientific or 
regulatory review”. 8  
Since 2008, the FDA has identified problems with several high-risk LDTs; however, many 
organizations have objected to the FDA’s oversight of LDTs, including the American Hospital 
Association, the American Cancer Institute (ACI), and the American Clinical Laboratory 
Association (CLA). The American Medical Association has stated “the FDA proposal will add an 
additional layer of regulatory requirements which may result in patients losing access to timely 
lifesaving diagnostic services and hinder advancements in the practice of medicine,” 9  
Certain professional organizations argue that the FDA lacks jurisdiction over LDT’s, and the CLA 
has argued, “The FDA requirements would stifle laboratory innovation and retard patient access 
to critical diagnostics.” 10  Moreover, the academic laboratories if held to the 21 CFR 820 standards 
may be required to perform clinical trials for each new genetic test developed. This process would 
require additional resources and as explained by Evans, (2015) “laboratories have insufficient 
resources to meet the proposed requirements and would essentially be precluded from developing 
or even improving tests in response to patient needs, clinician demands and changing 
technology.”10 
The FDA was given oversight and authority over in-vitro diagnostic medical devices in 
1976; however, regulatory oversight for laboratories remains with CLIA. 1, 17 
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Regulatory Overview 
Clinical Laboratory Improvement Amendment (CLIA) 
In this section, we highlight some of the important regulations that have led to the current 
framework governing LDTs.  First, we discuss CLIA, next the medical device amendment, the 
FDA quality system regulations and compare how those regulations differ from laboratory 
accreditation.  
The clinical laboratory has undergone progressive regulation over the past several decades, with 
key milestones depicted in Figure 1. The current regulatory framework has evolved from the 
Clinical Laboratory Improvement Amendments (CLIA) of 1967 and 1988, and is enforced under 
the direction of the Centers of Medicare and Medicaid Services (CMS).  The initial intent of the 
CLIA 1967 amendment was to establish licensing requirements for laboratories across state lines; 
however, the legislation for CLIA 88 was established to update requirements, implement 
performance measures and add personnel responsibilities.  Since 1988 the amendment has 
progressed to ensure validity, reliability, accuracy, and appropriateness of clinical laboratory 
testing and results.11 
 
 
Figure 1: Timeline of regulatory oversight 
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Although the aim of CLIA is to ensure that clinical laboratories operate suitably,12  Burd 
explains that CLIA lists the performance specifications as described in CFR 493 to be established, 
however, “does not specify the scientific methodology or implementation tool to be used.”12  CLIA 
instead defers selection of the appropriate methodology meeting these performance specifications 
to the Laboratory Director’s judgement.  Useful resources include not-for-profit agencies, like the 
CLSI, the College of American Pathologists (CAP), and the International Organization for 
Standardization (ISO), who develop and recommend clinical laboratory standards and 
accreditation criteria.12  To this end, the CLSI has recommended implementation of 12 Quality 
System Essentials (QSE) (Table 1) as a “framework to a systems approach to managing quality”.24   
The adoption of all 12 QSE will better ensure safe testing practices that align with governmental 
regulations. 
Table 1: CLSI Quality System Essentials 24 
 
1.     Organization 7.     Process Management 
2.     Customer Focus 8.     Documents and Records 
3.     Facilities and Safety 9.     Information Management 
4.     Personnel 10.  Nonconforming Event Management 
5.     Purchasing &Inventory  11.  Assessments 
6.     Equipment  12.  Continual Improvement 
Medical Device Amendment  
The medical device amendment was established in 1976 after 4.5 million Dalkon Shield 
intra-uterine devices sold between 1971-1974 adversely affected 900,000 women in the USA.25  
This device considered faulty was the impetus that promoted the establishment of FDA regulatory 
oversight to ensure the effectiveness of the intended use of medical device and to verify safe 
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manufacturing practices. The amendment required three classifications of medical devices: Class 
I- Low Risk medical devices; Class II- Moderate Risk; and, Class III- High Risk.  The regulatory 
approval process differs significantly for each class of device.  Class I devices require General 
Controls, Class II devices require pre-market notification (510(k)), and Class III devices require 
the most rigorous process of pre-market approval (PMA).  These classifications of medical devices 
have not been a concern for diagnostic laboratories until the FDA’s announced 2014 Draft 
Guidance for LDT. 26  
Quality System Regulation [21 CFR 820] 
The 21 CFR 820 or Quality System Regulation (QSR) is a regulatory requirement that 
directs the methods for the design, manufacture, packaging, labeling, storage, installation and 
servicing of medical devices to ensure their safety and efficacy. 2 The QSR encompasses 
organizational structure, management responsibilities, procedures, processes, and resources for 
establishing and maintaining a quality management system and serves as a guide for organizations.  
The 2014 LDT draft guidance proposes the use of this existing QSR.  However, LDTs differ from 
medical devices in three respects: 1) LDTs are considered by most outside of the FDA to be a 
medical service, not a device; 2) medical devices may be tested on human subjects and approvals 
may require additional time, processes, resources and regulatory requirements  3) Under the FDA, 
a device manufacture must demonstrate safety and efficacy of the product and may require 
verification through clinical trials for a (PMA) premarket approval for new devices or substantial 
equivalence for a (510K) predicate device. 1 
Differentiation Between Laboratory Developed Testing and Medical Device: Devices 
Cleared 
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The FDA cleared 2957 medical devices as 510(k) in 2012.27 The average approval time for 
FDA internal review in 2012 was 168 days.  As of September, of 2012 the FDA received 2965 
devices, of which, 1715 were rejected with a refusal rate of 58%.28  
In comparison, CLIA requires that tasks, activities and processes of diagnostic testing show 
accuracy and reliability of testing confirmed by validation of parameters and results. The FDA 
clinical trials are not equivalent to CLIA validation of testing parameters. 
Similar to CLIA, the FDA does not provide the operational design template, detailed instruction 
or translation from medical device requirements essential for interpreting, extrapolating, designing 
and implementing a QSR 
Table 2: Medical Device Requirements Regulation 26 
 
21 CFR 820 Quality System Regulation (QSR): Quality 
System Regulation requirements 
ISO 13485: International Standard- Regulatory Quality 
Management System Requirements for Medical Device 
Good Manufacturing Practices (GMP): Guidelines for 
manufacturing, testing, and quality assurance to ensure that a 
product is safe for human or animal consumption or use 
Good Laboratory Practice (GLP): Principles to assure the 
quality and integrity of non-clinical laboratory studies  
 
Comparing QSE to QSR  
Parallel to the QSR, the 12 QSEs contain most of the broad management categories and 
elements found in the 21 CFR 820 (Table 3 is a side by side comparison of QSE to QSR, showing 
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where they are equivalent and how they differ.). 41  However, the extent of their applicability to 
laboratories differ. Without a step-by-step guide for establishing the operational structure required 
to comply with the QSR, laboratories may feel they lack the resources and funding to develop a 
quality management program that meets FDA specifications. 
Table 3: Quality System Essentials in comparison to 21 CFR requirements 
 
12 Quality System Essentials (QSE)  21 CFR 820 Quality System Regulation (QSR) 
Organization  Management Responsibility 
Customer Focus   
Facilities and Safety   
Personnel  Personnel 
Purchasing and Inventory    Purchasing Controls 
Equipment   
 
Process Management   Process Controls 
Production and Acceptance Activities  
Design Controls 
Identification and Traceability 
Document and Records  Document Controls 
Information Management   
 
Nonconforming Event Management   Nonconforming Product 
Assessments  Quality Audit 
Continual Improvement   
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21 CFR 820: Understanding Design Control  
“Design Control” was originally established as a guiding methodology for the design, 
development, manufacture and production of medical devices to ensure accuracy, reliability and 
quality are consistently built into every new device.  The elements of 21 CFR 820 Design Control 
provide the manufacturing expectation of the FDA to produce a safe and effective product. 29  This 
methodology is an iterative process similar to product development methodology and although 
historically intended as a requirement for medical devices, the development of policies, procedures 
and processes as applied to test design should help with the establishment of design control specific 
to the laboratory. Figure 2.  lists each element of design control from development to design history 
and Table 4 lists each element of design control with a modified description for the practical 
application to organizational processes. (Appendix C.) 
 
Figure 2: Elements of Design Control for LDTs (21CFR 820) 
 
Table 4:  Description of Design Control 29  
 
21 CFR Design 
Control 
Description 
Design and 
Development 
Planning 
Procedure: Set of processes that transforms requirements for an object 
into more detained requirements. Such as the plan, design, development, 
execution, involvement and interface with different groups and 
responsibility (ISO 9001) 
Design Input Procedure: Product characteristics, requirements, intended use, user 
needs and the process to manage and resolve discrepancies is defined.  
Design & 
Development
Design 
Input
Design 
Output
Design 
Review
Design 
Verification
Design 
Validation
Design 
Transfer
Design 
Changes
Design 
History
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The process includes, responsibility approval, documentation and rational 
at every step  
Design Output Procedure: The output consists of technical, performance, specification 
and verification that the design successfully transferred into the testing 
environment  
Design Review Procedure: Describes the process to review all phases of the design with, 
documentation and approval all at each step. Establish and maintain 
procedures for the identification, documentation, and validation, 
verification, review, and approval of design changes before 
implementation  
Design * 
Verification 
Procedure: Describes the process that will ensure the test is safe, 
effective for use, conforms to the needs of the user and meets its intended 
use.  The process to ensure the design works as intended, has been 
verified, documented and approved at each activity 
Design 
Validation 
Procedure: The process operates as intended under defined operating 
conditions 
Design Transfer Procedure:  Describes the process of accurate transfer of the design into 
manufacturing requirements 
Design Changes Procedure: Describes the process to identify, track, document and 
approval changes prior to each activity 
Design History A means to track processing information pertaining to design, 
development, testing and links with all other design controls to 
demonstrate traceability and approval for each LDT manufactured 
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Medical Device 
Reporting (MDR) 
Procedure: Describes the process to identify, document and report an 
adverse event as an outcome of the test 
 
*NOTE: Verification pertaining to Design Control and Validation host two separate meanings in 
the laboratory. 37  
Verification: Confirmation, through the provision of objective evidence, that specified 
requirements have been fulfilled. (design output meets the design input requirements) 
Validation- Confirmation through the provision of objective evidence, that the requirements for a 
specific intended use or application have been fulfilled. 37, 38 
Research Methodology 
Now that we have covered the regulatory background, we turn to the technique conducted 
in this study as a mixed method approach to research employed in two sequential phases: Phase I 
consisted of qualitative interviews to capture the understanding of laboratory professionals in all 
aspects of LDTs and to determine if adherence to FDA regulatory requirements was achievable in 
a laboratory environment to design, develop, and test LDTs. If not, why not, and what would be 
the limiting steps.  
In addition to the interviews, proceedings from the 2 Day FDA Work shop “Framework 
for Regulatory Oversight of Laboratory Developed Tests(LDT)” 39 held January 8-9, 2015 also 
contributed to this study. The intent of the workshop was for the FDA to provide the rationale for 
the 2014 draft guidance, invite feedback and participation from peers within the laboratory 
community to state their case for or against the 2014 framework in context of the proposed 
regulatory requirements. The interview and workshop information assisted the researchers identify 
factors that would serve as the building blocks for a regulatory laboratory framework.  
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During Phase II a quantitative survey was conducted to test the factors identified during 
the interviews to determine agility, functionality, and usefulness as a proxy in the absence of 
implementation in a live environment.  
 The study was designed as follows: 
Phase I – Interview: A qualitative phone interview protocol was designed based on results of a 
review of the literature and was initially conducted to explore the potential challenges and 
constraints for laboratory compliance to the 2014 draft guidance. A convenience sampling strategy 
was used to select subject matter experts well versed in the historic, political and practical 
perspective of LDTs. The nine interview participants selected were professionals from the fields 
of laboratory, regulatory, accreditation, and medical device segments of the industry and who had 
the time or the availability to participate.   (Appendix A.) The names of the interviewees and 
associated organizations are retained as confidential. 
Secondary Data: The presentations obtained from the 2015 2 -Day FDA Work shop as it pertains 
to Quality System Regulation was documented, described and incorporated in this research. The 
public workshop was particularly helpful for this research and clarified issues and concerns as well 
as provided insight about future regulatory direction, strategy, and explained how FDA 
recommendations may affect future laboratory operations. 
Constructing the Interview Protocol 
The interviewees were asked the questions in the following protocol and were encouraged to 
discuss their knowledge of LDTs. The 30-minute confidential interview protocol consisted of nine 
questions (Table 5). (Appendix B.) 
Table 5: Interview Questions 
 
1. What is your role, title, and responsibility in the organization? 
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2. Tell me about the history and your knowledge about of Lab developed Tests? 
3. What are some of the regulatory challenges associated with LDT’s? 
4. How does genetic testing influence regulatory oversight? 
5. Describe the current scrutiny associated with regulatory guidelines for LDT’s? 
6. What is the role of the FDA in lab developed tests? 
7. Explain the intent of the FDA guidance framework for LDT’s released December 
2014? 
8. In your opinion, what would the implications(s) be if the FDA mandated regulatory 
guidelines for the process of LDT’s? 
9. How would you describe the “outcome and view of the future” if the FDA mandates 
regulatory oversight for LDT’s?  
Data Collection 
The interviews were conducted by telephone over a two-year period from April 2015-May 
2017. The process was explained prior to the interview, was audio-recorded when possible, and 
the results compiled. In addition to interview data, secondary data was collected from discussions 
that pertained to the quality system regulation during the public workshop to capture concerns with 
the 2014 draft guidance.  
Data Analysis 
The interviews were conducted with nine participants and the discussions were manually 
transcribed. The topics of the conversations were tallied for frequency and coded manually. As 
depicted in Table. 7 the interview and secondary data were categorized into codes and sub-codes, 
and a relational analysis was conducted to identify patterns of the most frequent theme and trends 
in both the interviews and the workshop discussion. 
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Phase II Survey: Testing the Functionality of the Framework 
Constructing the Survey Protocol 
A confidential Qualtrics Survey consisting of three sections was developed for this study. 
Section I includes survey statements derived from extensive literature searches, the qualitative 
interviews and a review of the 2015 2 - day FDA workshop pertinent to the QSR on Laboratory 
Developed Tests. Based on feedback, we translated the findings into a taxonomy comprised of 
eight strategic factors and 40 statements that serve as building blocks for a laboratory regulatory 
quality management system. As depicted in Appendix G, each statement contains five statements 
totaling 40 outcomes ranked on a 5 point Likert scale from “extremely important” to “not important 
at all”. 
The strategic factors identified are as follows: 
1. Leadership commitment 
2. Training 
3. Pre-assessment of the current QMS 
4. Design Control 
5. Document Control 
6. Process Control 
7. Development of a QMS framework 
8. Process validation 
Section II contained two open-ended questions regarding the functionality, agility and usefulness 
of the strategic factors listed in the study. The feedback was instrumental in determining if the 
participants agreed with the factors included in the survey or in assessing their opinion about what 
factors would be more appropriate.  
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1) Do you agree with the strategic factors identified in the proposed framework for a Quality 
Management System of LDTs? If not, please suggest additional factors pertinent to develop a 
robust framework 
2) Do you think the establishment of a Quality Management System framework will assist LDT 
laboratories incorporate regulatory requirements such as design control more readily? If not, why 
and what else is necessary?  
Section III included two questions to substantiate the understanding of the respondents regarding 
LDT design, development, validation and delivery in a laboratory environment, and to document 
their professional role. The questions were as follows: 
1. What is your professional role? 
a. Senior leader 
b. Medical Director 
c. Medical Doctor 
d. Technical Supervisor 
e. Manager/Supervisor 
f. Quality Professional 
g. Other 
2. Do you consider yourself a subject matter expert on the topic of LDT? 
a. Definitely yes 
b. Probably yes 
c. Might or might not 
d. Probably not 
e. Definitely not 
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Data Collection 
The quantitative survey was distributed to 767 laboratory professionals from April- July, 
2017. The respondents included all attendees from the Executive War College Laboratory 
Conference held in May 2017 in New Orleans, LA.  The survey was also distributed to randomly 
selected laboratory professionals demonstrating expert knowledge regarding the field of LDTs 
from LinkedIn with titles in the fields of regulatory, quality and medical laboratory.  
Survey Demographics 
The responses from the Qualtrics survey resulted in 51 started surveys and 35 completed 
surveys with a 69% completion rate of those who responded to the survey. The respondents 
included 10 senior leaders, four medical directors, 13 quality professionals, two technical 
supervisors, one manager and five other professionals. To ensure the appropriate expertise in the 
field of LDTs each participant was asked a critical qualifying question: Do you consider yourself 
a subject matter expert in the topic of LDT?  Nine participants responded, “Definitely yes”, nine 
“Probably yes”, six “Might or Might not”, seven “Probably not” and two “Definitely not” as 
depicted in Table 6. 
Table 6:  LDT Expert classification of survey respondents 
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Data Analysis 
The statistical software SPSS Version 24 was used to calculate and analyze the scores for 
significance across all eight factors and 40 statements. The descriptive statistics include the mean, 
standard deviation and variance. Additional statistical analyses are as follows: 
Principal Axis Factoring extraction method 
The data was further analyzed by the Principal Axis Factoring extraction method, more 
specifically Principal Component Analysis with the Rotation Method: Varimax with Kaiser 
Normalization.  According to Williams, (2010) isolating factors with high loadings can reduce the 
variables into a smaller set of factors, remove variation and cluster the relationships into patterns. 
This method was helpful to identify patterns consisting of high loadings with significant factors 
and statements exceeding 0.623 as depicted in Table 9. 40  
T-Test 
The T-test was performed to determine whether the means of experts and non-experts had 
distinct, differing priorities and were statistically different regarding the adoption of a QMS.  Since 
the participants rated four of five factors within the leadership commitment as the most relevant 
category, the assumption was the experts may have answered the statements differently due to 
their roles and responsibilities within the organization. The non-experts were operationally 
oriented rather than occupying a leadership role. To test this assumption, the data was analyzed to 
determine if experts and non-experts chose statements within the eight strategic factors differently.  
Open –ended questions 
The responses to the open-ended questions were analyzed using SPSS Version 24 to 
determine the number of participants considered an expert (Table. 6) and to tally acceptability and 
satisfaction with the suggested factors as explained in the survey results section. 
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Results 
Interviews 
The tone expressed by the  interviewees was ambiguity and uncertainty regarding all 
aspects of the LDT process and similar concerns were articulated, including: 1) risk classification, 
2) process validation to ensure the accuracy and precision of tests results, 3) the ambiguity of the 
21 CFR 820 requirements translated to the laboratory 4) lack of clarity from the FDA and other 
governmental agencies (e.g., CMS) 5) the patient safety concerns of the FDA 6) lack of clarity and 
direction regarding the 2014 draft guidance. 
The lack of coordination, clarity and guidance from CLIA and the FDA has created 
confusion and a lack of motivation on behalf of the laboratory community. The general feedback 
received through the interviews showed substantial ambiguity across laboratory professionals 
regarding terms, definition and how to transfer operational requirements into regulatory terms. In 
addition, it is unclear how the draft guidance would translate from medical device to the laboratory. 
The development of a laboratory application of 21 CFR 820 quality systems regulation that would 
meet the LDT manufacturing requirements has not been addressed by regulatory agencies and has 
left laboratory leaders unprepared to be proactive. Ambiguity also existed during the interviews 
regarding the definition of design control and how to appropriately address and translate these 
requirements into the laboratory environment.  
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Interview Results 
Figure 3: Interview Results 
The discussion with the interviewees was instrumental to gain an understanding of the 
challenges faced by laboratory leaders, accreditation agencies and regulatory policy makers.  The 
interview findings depicted in Figure. 3 illustrates the basis for the development of an operational 
framework for LDT.  (Appendix F.) 
The top 5 most significant concerns are identified as follows: 
1. FD-RC: Risk Classifications 
2. FD-PV: Process Validation 
3. FD-21 CFR 820 QSR Requirements 
4. GEN-UCT: Uncertainty 
5. GEN-PT: Patient Safety  
Table 7: Leading Interview Codes 
 
Code Category 
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General  
GEN- HT History of LDTs 
GEN- TN Technology 
GEN- PT Patient safety concerns 
GEN-DIR The laboratory need for direction 
GEN- BM Change business model 
GEN-UCT Uncertainty of requirements and path forward 
  
LAB  
LAB-Org  Hardship to organization 
LAB-ACC  Accreditation requirements 
LAB-QS   Quality Management Systems  
  
FDA  
FD-RC Risk classifications 
FD-PV  Process validation 
FD-FRW FDA 2014 Framework proposal 
FD-OS Outsource may be necessary 
FD-RS Resources are needed to comply with regulations 
FD-CFR  21 CFR 820 QSR requirements 
 
Secondary Data 
FDA Public Workshop  
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The information shared during a 2 day FDA webinar held January 8-9, 2015 made a 
significant contribution to this research. 39 The FDA began the conference by addressing areas of 
concern regarding the overview of LDTs draft guidance and the implication of adverse test results 
for the patients and the laboratories, and how the guidance would affect regulatory agencies 
already lacking appropriate resources. The director of the Centers for Devices and Radiological 
Health Jeffrey Shuren, stated that the “FDA is transparent and does not claim they got it all right 
and some say they didn't get anything right”. However, the FDA is acting on the behalf of patient 
safety, which has made its way into the popular press.  39  In fact, Adverse patient safety concerns 
associated with LDT was published in literature: New York Times Aug. 28, 2008, July 7, 2011 
and January 22, 2011. 39  Guest speakers shared their support and apprehension of the draft 
guidance and addressed the importance of test accuracy for appropriate therapies.  Katherine 
Tynan, (2015) 
 39 a presenter stated “Quality systems vary significantly in terms of scale and 
complexity, and one of my concerns with the current dialogue between the FDA and laboratories 
developing LDTs is that quality means very different things to the stakeholders”. 
Research and Development firms stressed the importance of laboratories outside of 
manufacture to be held to the same regulatory oversight and stated that a major cause of the 
inaccuracies of laboratory test development is improper design and lack of validation to verify the 
result is as intended. This topic was substantiated by consistent feedback mentioned 12 times from 
all nine interviewees also expressing test validation concerns.  Liz Lison, president of Advocea 
Consulting firm (2015) and a conference speaker explained, “Most of the failures that I have seen 
in LDTs may have been averted if design controls had been in place. Therefore, I urge the agency 
not to delay the enforcement of design controls for high-risk tests and potentially introduce a two 
-tier system for pre-market review.” 39  
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The oversight of laboratory testing remains with CLIA.  However, a gap exists regarding 
the regulation of test development. Due to the advances in genomic medicine the interviewees 
expressed that the oversight by CLIA is no longer adequate to manage the compliance needs of 
laboratories. There is a significant difference in the oversight of the FDA and CLIA.  The FDA 
does not mandate the operation of testing as stated in CFR 493; CLIA does not ensure the safety 
and effectiveness of test protocols as described in 21 CFR 820 41  
Results 
Secondary Data  
 
Figure 4:  Secondary Data Results 
 
Interpretation of Findings 
The interview and secondary findings validated the motivation for this study.  The 
laboratory professionals illustrated the struggle to understand how to develop and organize a 
framework adaptable to their organization.  The participant response from the 2-day work shop 
was more directive and outlined the need of laboratories versus the uncertainty noted during the 
interviews. As a result, the participants substantiated the need for a regulatory vocabulary 
translated to operational laboratory terms.  In addition, the feedback describing gaps in processing 
was instrumental to the development of strategic factors developed from interview and workshop 
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feedback and proposed as the precursor to a quality systems framework that would serve as the 
foundation for LDT development as depicted in Table 8:  
Table 8:  Suggested strategic factors necessary for a regulatory QMS framework 44 
 
Topic Interview/Conference Discussion 
Strategic Factors 
developed as a 
result of the 
interviews 
Interview 
Topic 
Leaders are unclear regarding how 21 CFR 820 
requirements applies to laboratory testing considered by 
many to be a service, not a product. 
Leadership 
Commitment 
Interview 
Topic  
Laboratories lacked the rigor that is present in the 
manufacture of medical devices.  
Training 
FDA Public 
Workshop 
 It is essential that FDA harmonize the QSR requirements 
with CLIA requirements at a more granular level to 
prevent duplicate efforts and to ease the regulatory 
burden” because governmental agencies have not provided 
the necessary guidance for struggling laboratories 
Pre-assessment of 
the existing 
Quality 
Management 
System 
FDA Public 
Workshop 
Laboratory failures due to lack of process control  Design control 
FDA Public 
Workshop 
Change is necessary to raise the level of quality, prioritize 
tasks and dedicate the time and resources necessary to 
understand regulatory requirements in order to attain 
process standardization. 
Document control 
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Interview 
Topic  
The major cause of the inaccuracies of laboratory test 
development is improper design and lack of validation to 
verify the result is as intended. 
Process control 
FDA Public 
Workshop 
Laboratories need a guidance documents and a defined 
process to simplify and translate FDA proposal 
Development of a 
QMS framework 
Interview 
Topic  
The importance of test systems to validate protocols, 
processes and test development that will consistently 
ensure the effectiveness and accuracy of test results 
Process Validation 
 
Survey Results  
Exploratory Factor Analysis and Factor Reliability  
The factor analysis was conducted to explore the data set, determine the importance of the 
relationships between the variables and isolate the factors with high loadings to reduce variables 
into a smaller set of factors. As described by (Williams, et al, 2010) an appropriate factor load of 
0.50 is optimal for factor analysis. However, due to the smaller sample size a significant factor 
loading would be 0.60 or larger. 40 The analysis eliminated 17 variables with smaller loadings as 
shown in Table 9.  The loadings analyzed and clustered the relationships into patterns. The clusters 
illustrated the importance of leadership, clinical validity, process validation, and procedures to 
provide guidance for accuracy and consistency of processes.  The weak factors removed clarified 
the reluctance to perform a pre-assessment of the existing operation to determine if the 
organization was prepared to operate within a regulatory environment.   
Table 9: Exploratory Factor Analysis and Factor Reliability performed on each category 
 
Rotated Component Matrixa          
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Statement Statement Description Component         
  1 2 3 4 5 6 7 8 9 
Q2_4 Staff training  0.822         
Q3_3 Crosswalk of current 
processes 
0.772         
Q3_5 Clear understanding of 
QSR requirements 
0.701         
Q2_5 The assignment of 
responsible persons 
0.691         
Q7_3 Pre-assessment of 
current processes 
0.635         
Q5_4 Documentation of tasks 
and activities at each 
step 
0.626         
Q2_3 The program includes 
value stream mapping 
to demonstrate the 
significance of handoffs 
0.614         
Q3_2 ISO 15189 will assist 
the organization 
comply to requirements 
0.612         
Q7_4           
Q7_5           
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Q6_4 Clinical validity is 
performed as validation 
 0.811        
Q6_3 Documentation of 
analytic validity will 
demonstrate accuracy 
and reliability 
 0.765        
Q6_1 Responsibility for every 
handoff to ensure LDT 
accuracy 
 0.615        
Q1_3           
Q5_5           
Q8_3 Process qualification 
ensures design 
specification 
  0.871       
Q8_2 Validation to ensure all 
steps meet regulatory 
requirements 
  0.779       
Q8_4 Operational 
qualification will 
ensure the process is 
operating as intended 
  0.675       
Q7_1           
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Q5_2 Clearly written 
procedures remove 
ambiguity in the 
process 
   0.859      
Q5_1 Updated and accurate 
operating procedures 
   0.761      
Q1_4           
Q3_1           
Q8_5 Performance 
qualification produces 
the same result and 
operates correctly 
    0.696     
Q2_1 Training includes 
introduction to LDTs 
    0.659     
Q8_1 Process validation is 
performed to ensure 
effectiveness  
    0.626     
Q2_2           
Q1_2           
Q4_3 Design control well 
implemented and 
documented will ensure 
quality 
     0.759    
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Q4_2 Design control 
described in laboratory 
terms will clarify 
requirements 
     0.724    
Q7_2           
Q4_4           
Q6_5 Data collection and 
clearly communicating 
requirements 
      0.863   
Q6_2 The consistent 
uninterrupted flow of 
material will 
demonstrate user 
friendliness of the 
framework 
      0.764   
Q5_3           
Q1_1 Leadership institutes 
key performance 
indicators 
       0.699  
Q4_5 A procedure that 
address adverse events 
       0.665  
Q3_4           
Q4_1           
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Q1_5 Leadership consistently 
communicate change 
        0.734 
          
Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser 
Normalization. 
a. Rotation converged in 15 iterations. 
Over all Mean of Categories  
To determine if factors were viewed differently by experts versus non-experts the 
aggregate mean for the items associated with each factor was analyzed. As sown in Table 10, 
experts versus non-experts chose similar responses for all statements within the survey from an 
average of close to one – extremely important to slightly over two- very important. This result 
suggests both groups considered all factors to be equally important for the development of a QMS. 
(Appendix. VII) 
Table 10: Over all Mean of Factors 
 
N Range Minimum Maximum Mean
Std. 
Deviation Variance
AverQ3_Preassess 33 2.40 1.00 3.40 1.9515 0.58101 0.338
AverQ4_DesignContrl 33 2.20 1.00 3.20 1.9455 0.60472 0.366
AverQ5_DocuentContrl 33 2.00 1.00 3.00 1.9030 0.58335 0.340
AverQ7_Development 32 1.80 1.00 2.80 1.8844 0.42435 0.180
AverQ6_ProcesContrl 32 1.60 1.00 2.60 1.8453 0.45497 0.207
AverQ2_training 33 1.40 1.00 2.40 1.8364 0.40452 0.164
AverQ8_ProcessValid 33 1.80 1.00 2.80 1.7212 0.48718 0.237
AverQ1_Leadership 33 1.20 1.00 2.20 1.5333 0.32275 0.104
Valid N (listwise) 32
Descriptive Statistics
 
T-Test Factor Analysis 
As shown in Table 11, the mean responses to the factors by experts versus non- experts. 
The hypothesis was experts and non-experts had different and distinct priorities regarding adoption 
of a QMS due to their roles and responsibilities within organization and may have answered 
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statements differently.  We found that there was no significant difference between experts and 
those of non-experts on average importance attributed to the strategic factors. 
Findings: No significant difference between the responses of experts and non- experts.   
Table 11:  T-Test Results 
 
Lower Upper
Equal 
variances 
assumed
1.026 0.321 -0.258 25 0.798 -0.03333 0.12910 -0.29922 0.23255
Equal 
variances 
not 
assumed
-0.280 19.907 0.783 -0.03333 0.11921 -0.28208 0.21542
Equal 
variances 
assumed
0.082 0.777 0.543 25 0.592 0.08889 0.16366 -0.24818 0.42596
Equal 
variances 
not 
assumed
0.572 18.466 0.574 0.08889 0.15549 -0.23718 0.41496
Equal 
variances 
assumed
0.032 0.859 0.504 25 0.619 0.12222 0.24273 -0.37769 0.62214
Equal 
variances 
not 
assumed
0.528 18.308 0.604 0.12222 0.23135 -0.36324 0.60768
Equal 
variances 
assumed
0.293 0.593 -0.946 25 0.353 -0.24444 0.25843 -0.77669 0.28780
Equal 
variances 
not 
assumed
-0.886 13.663 0.391 -0.24444 0.27581 -0.83737 0.34848
Equal 
variances 
assumed
0.928 0.345 -0.828 25 0.415 -0.20000 0.24148 -0.69733 0.29733
Equal 
variances 
not 
assumed
-0.893 19.659 0.383 -0.20000 0.22406 -0.66790 0.26790
Equal 
variances 
assumed
1.221 0.280 0.088 24 0.931 0.01667 0.18916 -0.37374 0.40708
Equal 
variances 
not 
assumed
0.100 18.558 0.921 0.01667 0.16651 -0.33240 0.36574
Equal 
variances 
assumed
0.003 0.958 -0.310 24 0.759 -0.05556 0.17922 -0.42545 0.31434
Equal 
variances 
not 
assumed
-0.327 15.388 0.748 -0.05556 0.16980 -0.41669 0.30558
Equal 
variances 
assumed
0.901 0.352 -0.272 25 0.788 -0.05556 0.20443 -0.47659 0.36548
Equal 
variances 
not 
assumed
-0.244 12.335 0.812 -0.05556 0.22808 -0.55100 0.43989
Independent Samples TestLevene's Test for 
Equality of Variances t-test for Equality of Means
F Sig. t df
Sig. (2-
tailed)
Mean 
Difference
95% Confidence Interval 
of the Difference
AverQ6_Pr
ocesContrl
AverQ7_De
velopment
AverQ8_Pr
ocessValid
Std. Error 
Difference
AverQ1_Le
adership
AverQ2_trai
ning
AverQ3_Pr
eassess
AverQ4_De
signContrl
AverQ5_Do
cuentContrl
 
Survey Results: Expert Response per Quartile  
The survey results for the most important rated statements with corresponding means as 
depicted in Figure 5. begins with Leadership Commitment as described for statements, one, two, 
three and five. (Appendix F.) The commitment of leadership to institute key performance 
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indicators, direct regulatory initiatives and maintain and consistently communicate change in the 
organization was considered significant. However, a poorly rated statement was the task of an 
organizational pre- assessment to determine missing processes, lack of procedures, deficiencies 
and create a list of necessary guidance documents to comply to regulatory requirements.  This 
outcome was unanticipated due to laboratory accreditation agency practices of a cross walk 
between laboratory current processes in comparison to requirements. Statements depicting design 
control were not considered extremely important with all five statements located on the second, 
third, and fourth quartile, despite the proposal for QSR by the FDA. There were no significant 
results for the following statements: 1) the statement suggesting a procedure to address the process 
for identification, documentation and reporting of an adverse event in the laboratory and the 2) 
establishment of an LDT quality committee to quickly approval changes and provide support.  
Respondent Feedback  
The open -ended questions presented to the survey respondents in Q9, Do you agree with 
the strategic factors identified in the proposed framework for Quality Management System of 
LDTs? If not, please suggest additional factors pertinent to develop a robust framework. This 
question resulted in positive feedback for the development of a QMS framework and 20 of 35 
participants agreed with the strategic factors proposed by the researcher. The respondents agreed 
that all the factors and statements listed were indeed important. However, leadership buy in was 
considered imperative for implementation and to ensure the proper resources to address 
development of the QMS.  
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Q1																																																
Leadership	
Commitment
Q2																																																						
Training
Q3																																																													
Pre
assessment	of	
exsisting	QMS
Q4																																								
Design	
Control
Q5 																								
Document	
Control																	
Q6 																							
Process	
Control
Q7																							
Development	
of	a	QMS	
Framework
Q8																																							
Process	
Validation
Mean
1.28 Q1_5
1.3 Q1_1
1.33 Q1_2
1.39 Q1_3
1.44 Q6_4
1.5 Q8_3
1.56 Q7_1 Q8_2
1.61 Q2_2 Q5_5 Q6_3
1.67 Q4_3 Q8_1
1.67 Q8_4
1.71 Q7_5
1.72 Q3_5 Q4_1 Q5_1
1.78 Q5_2 Q8_5
1.82 Q6_1
1.83 Q2_5 Q7_3
1.89 Q3_2 Q4_2 Q7_2
1.89 Q4_4
1.94 Q2_1 Q3_1 Q5_4
2 Q2_4 Q6_5 Q7_4
2.06 Q1_4 Q2_3 Q5_3 Q6_2
2.17 Q3_3
2.22 Q3_4
2.28 Q4_5
Statement
Q1
Q2
Q3
Q4
 
Figure 5: Quartile split of Survey Statements by Expert Participants 
 
Feedback- The Establishment of a Quality Management System Framework 
The question presented to the survey respondents in Q10 - Do you think the establishment 
of a Quality Management System framework will assist LDT laboratories incorporate regulatory 
requirements such as design control more readily? If not, why and what else is necessary? Out of 
35 respondents 23 answered this question with yes, I agree and strongly agree and nine of 35 
respondents scripted favorable feedback. The respondents agreed that a fully functional QMS is 
needed to meet accreditation requirements and document control is critical in this process. An 
accepted framework will provide the laboratory community “structure, uniformity and integrity” 
(survey respondent) and the documentation discipline for all laboratories.  The process is not only 
beneficial for the development of LDT but in the general lab as well to comply with accreditation 
requirements.  A crosswalk of each clause of Part 21 CFR 820 can be performed in comparison to 
the elements of each QSE. The QSE can be used as the QMS framework; however, the most 
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difficult topic discussed in the draft guidance is clinical significance and how the results derived 
from a LDT are being used or will be used to guide therapy. 
Discussion 
The impetus for change within the laboratory community began with the awareness of 
patients that were adversely affected by the results of a Laboratory Developed Tests. Historically 
the design and development of LDTs was not under the jurisdiction of CLIA and testing operations 
are formally not within the oversight of the FDA.  Many articulated the FDA has no jurisdiction 
over LDTs. In addition, before synergistic legislation can occur the agencies must bridge the gap 
between required regulations. Shelia Walcoff of Goldbug Strategies (2015) and a FDA Work Shop 
speaker stated that “It is essential that FDA harmonize the QSR requirements with CLIA 
requirements at a more granular level to prevent duplicate efforts and to ease the regulatory 
burden” because governmental agencies have not provided the necessary guidance for struggling 
laboratories. 39  The adoption of a laboratory structure that would satisfy accreditation and 
regulation requirements in the event the 2014 draft guidance becomes a policy is perplexing. The 
interviewees expressed that laboratories may be required to change business strategies, outsource 
or terminate many of the current tests if the FDA proposal becomes a policy. 
However, interviewees also expressed that laboratory leaders are taking the wait-and-see 
approach because the laboratory community considers test development a service, not a product.  
The interviewees shared their concerns for CLIA and the FDA to collectively develop standards 
and guidance documents prior to a policy release.   The current regulations for medical device 
include requirements for design control geared for product development and the meaning of design 
control, methodology and the translation of these regulations from the medical device industry to 
a clinical laboratory do not exist.  The survey respondents agreed that a regulatory oriented 
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framework for the development of LDTs is needed in the laboratory and it is interesting to note 
that the survey respondents did not consider design control as extremely or very important despite 
the proposal for a QSR by the FDA. These findings support the conclusion of ambiguity 
interpreting the meaning of design control and how this requirement would be adapted to the 
laboratory environment.  Liz Lison, president of Advocea Consulting firm (2015) and a FDA Work 
Shop speaker explained, “Most of the failures that I have seen in LDTs may have been averted if 
design controls had been in place. 39   
The eight suggested strategic factors and 40 statements derived from the literature, 
qualitative interviews and the FDA work shop provide the impetus for design of an QMS. The 
respondents agreed with all statements relevant to the design of a QMS based on needs and gaps 
expressed by laboratory professionals. This finding aligns with the results of the survey as there 
was no significant difference in the way the experts verse non- experts responded to factors and 
associated statements. All respondents chose statements as 1) extremely important or 2) very 
important.  This finding directly aligns with the recommendation by Katherine Tynan, an 
independent regulatory consultant from the 2015 FDA workshop that offered advice to 
governmental agencies as follows: 
1. “Develop a common vocabulary that laboratories can understand” 
2. “Simplify the cumbersome QSR and assist laboratories translate the directives”  
3. “Develop a “QSR fit for purpose and harmonize the standard” 
Tynan’s advice to laboratories was to “invest in a quality management system, implement all 
factors of design control, and be proactive and prepare for future regulatory requirements.” 39  
Consequently, the preparation of a QMS require the understanding of where gaps exist to 
develop appropriate processes that would to adhere to requirements. Moreover, this survey 
 46 
 
statement suggesting review of current policies and procedures to identify gaps was not considered 
important by all groups. This was an interesting conclusion because this is general practice within 
laboratory accreditation agencies.   
The future research includes design of an agile, robust quality management system that 
will incorporate the suggested factors as follows:  leadership commitment, training, pre-
assessment, design control, document control and development of a QMS framework.  
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CHAPTER 4. DESIGNING A REGULATORY AGILE QUALITY MANAGEMENT 
SYSTEM FOR DEVELOPMENT OF LABORATORY DEVELOPED TESTS 
 
Change will not come if we wait for some other person or some other time. We are the ones we've 
been waiting for. We are the change that we seek.  -Barack Obama 
Overview  
This chapter continues the call for action by assisting leaders to prepare for a regulatory 
QMS. We address the concerns of the laboratory community and discuss the current position of 
regulatory agencies. Our premise is to prepare, because this issue holds the likelihood to effect 
patient safety and as expected, may not go away. We provide step by step instruction to design a 
QMS. This manuscript was sent for publication in the American Journal of Clinical Pathologists.  
Introduction 
The position of the Federal Drug Administration (FDA) for the oversight of laboratory 
developed tests has evolved since the issued 2014 draft guidance entitled Framework for 
Regulatory Oversight of Laboratory Developed Tests.2   This 2014 draft guidance proposing 
oversight for laboratories that manufacture in house LDT was fully supported by physicians, 
pharmaceutical firms, IVD manufactures and insurers, however, received significant objection and 
opposing public opinion by the laboratory community.42  To neutralize public opinion, the FDA 
published a discussion paper dated January 13, 2017 and some claim the oversight by the FDA 
may be on hold, however, Gatter, (2017) has stated “it is unlikely that the issue is over”. 42   In fact, 
in a January 13, 2017 discussion paper the FDA indicates support for CLIA requirements 
regardless of the dissimilarity to 21 CFR 820 Quality System Regulation (QSR) requirements. The 
paper describes three QSR recommendations “consistent with the approach described in the 
discussion paper” 6  for laboratories that develop LDTs. These quality system regulations address 
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requirements for test development not mandated by CLIA regulations: These requirements 
include: 
1. Design Control – “an interrelated set of practices and procedures that are incorporated into 
the design and development process, i.e., a system of checks and balances and make 
systematic assessment of the design an integral part of development” 5  
2. Acceptance Activities – “adherence to requirements through inspections, assessments, or 
other verification” 41  
3. Corrective and Preventative Action – The process to investigate the cause of occurrences 
in the lab to ensure documentation, correction and follow up is performed.41 
This recommendation, if implemented will constitute a proactive approach to process 
standardization and compliance to the adoption of a QSR framework.  However, many 
laboratorians are unclear “how to” interpret, extrapolate, design and implement a QSR and the 
instruction has not been provided. In addition, laboratories are unclear how the framework written 
from a medical device perspective can relate to diagnostic laboratories. 44  Furthermore, to the 12 
Quality system essentials, the nonexistence of a template, guidance document or standard approach 
to development of a quality management system (QMS) aligned with accreditation requirements, 
has resulted in “various levels of quality” within laboratories.12    Laboratories resort to reinventing 
the wheel or adopt practices aligned with process standardization such as the implementation of 
ISO 9001, ISO 17025 and ISO 15189 specific to medical laboratories.12  Although, these 
documents provide guidance, the successful implementation of process standardization is based 
on the support of leaders to own and drive an organic, directed initiative with tasks and activities 
applied to local specific organizational processes. The standardization of successful organic 
processes can be found described in an early interpretation of a Deming management philosophy, 
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known as Total Quality Management (TQM). Systematic standardization, top leadership 
commitment and continuous improvement throughout the entire organization was at the heart of 
the successful application of Deming management principles as applied to the Toyota Motor 
Corp.35  However, it was noted that many laboratory leaders are taking the wait and see approach 
to implementation of a standardized process that would embark on a framework in preparation for 
QSR requirements.44  
Contribution: In this paper, we continue the call for action for proactive leadership commitment 
to prepare for regulatory requirements for laboratories that develop LDT.  We propose the design 
of a regulatory QMS framework, bridge the gap and illustrate expansion of the 12 QSE to include 
the factors identified by a previous survey deemed to be optimal for a robust QMS. 44 To avoid 
duplication, we clarify, translate and integrate pertinent 21 CFR 820 design Control from the 
medical device industry to the diagnostic laboratory framework.1  Finally, we illustrate and 
propose expedited test development with the customization of an agile stage gate hybrid 
methodology from product development to the laboratory. 
Prior Research Findings  
In our prior LDT publication, we reported results of a study to explore the concerns of the 
laboratory community specific to the quality system regulations described in the 2014 draft 
guidance. 44  The aim was to understand if compliance was possible, and if not, why and what 
would be the limiting step. The interview responses obtained from laboratory professionals with 
significant expertise in the field of LDTs expressed ambiguity regarding the FDA draft guidance 
and questioned the meaning and adaptability of design control. In addition, they were unclear how 
the requirement proposed by the FDA in the Quality System Regulation in general would translate 
to the laboratory environment. The opinion of the professional interviewees expressed that 
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laboratories offer a service, not a product and the QSR does not equate to the laboratory 
environment.1  The 2015 FDA Workshop on Laboratory Developed Tests (Jan 8-9, 2015) also 
included speakers offering direction and encouragement to the FDA to oversee the process of 
LDTs for patient safety and offered advice for laboratories to begin to prepare.39  
The authors explored the FDA regulatory requirements described in 21 CFR 820, defined 
and clarified the terms and compared the directives to the 12 Quality System Essentials as 
recommended by the CLSI. As we researched the translation of medical device requirements to 
laboratories, we found commonalities in the manufacturing factors, however, we further identified 
unaddressed gaps. As the result of qualitative interviews, literature searches and survey feedback, 
eight strategic factors and 40 supporting statements were developed that addressed the gaps and 
needs of laboratories. We tested the factors using a survey instrument for functionality, usefulness 
and agility and all 35 participants agreed that the strategic factors were optimal for development 
of a Quality Management System (QMS) regulatory framework.   The survey respondents agreed 
with the importance of leadership commitment for LDT, however, the results of the interviewees 
yielded leaders that are taking the wait and see approach as opposed to being proactive.  
What is a Quality Management System? 
A Quality Management System (QMS) is “an integrated framework through which 
organizations systematically define quality objectives linked to their broader strategic goals and 
develop and implement foundations, organizational structures and processes to achieve these 
objectives.” 45 
The primary and most important step in the design of an integrated framework for QMS is 
the need for a clear understanding of the terms and definitions of regulatory requirements pertinent 
to the operation.  In addition, Luzack (2012) describes the most important factor to be leadership 
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commitment to dedicate the time and resources necessary to develop the documents within the 
QMS that will direct and control all other activities.46   A significant benefit of a QMS is the 
adherence to the strategic goals by horizontal control and shared roles across the entire 
organization responsible for quality. As stated by Meeker et al. (2015), an integrated and flexible 
QMS framework would proactively and strategically prevent and/or reduce risks in quality; a 
significant benefit for the patient. 45  
Material and Methods 
Designing a Quality Management System 
The design of a Quality System Regulation (QSR) or a Quality Management System 
(QMS) is proposed based on six steps as depicted in Table 12. and are further described below 
(note that terms QSR and QMS are used interchangeably in this text). 
Table 12: Steps to Create a Quality Management System 
 
Step Method 
1 Understand the requirements 
2 Cross reference the existing 12 Quality System Essentials to match the common 21 
CFR 820 clauses 
3 Perform an initial assessment to determine current laboratory policies, procedures and 
processes  
4 Develop and implement policies, procedures, processes that describe direction for each 
requirement 
5 Implement tasks associated with stage gate, agile hybrid methodology and assign a 
responsible person(s) to perform a formal go/no go decision at each handoff of design 
controls  
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6 Develop a Quality Management System framework to include all the above 
 
Step 1: Understand the Requirements  
The initial step to developing a regulatory QMS is to understand the regulatory 
requirements as they relate to the context of a particular organization. In addition, mission and 
vision statements will provide insight regarding the nature of operations—forensic, high 
complexity, high risk/ low risk, rare diseases, and LDT types. 
Step 2: Cross Reference the QSE to the QSR  
The elements covered by the 12 QSE and the clauses in the QSR are listed in Table 13. 
The QSE contain most of the broad management categories included in the 21 CFR 820. The 
majority of the 12 QSE’s should already exist in some form in many laboratories; however, the 
extent of laboratory application may differ. 24  For each QSE depicted in Table 13, identify the 
QSR on the right that most closely adheres to the activities in that QSE management principle.  
Identify any outliers or unaddressed clauses. For example:  
1. (QSE) Organization: (management oversight) = (CFR) Management Responsibility   
2. (QSE) Occurrence Management = (CFR) Nonconforming product + 
Corrective/Preventive Actions 
To further clarify requirements, Table 14. depicts a cross reference of QSEs and QSRs and lists 
many of the common activities associated with requirements for laboratory accreditation. 
Table 13: The 12 QSE and 21 CFR 820 requirements 
 
12 Quality System Essentials (QSE) CFR 820 Quality System Regulation (QSR) 
Organization Management Responsibility 
Personnel Quality Audit 
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Equipment Personnel 
Purchasing and Inventory Design Controls 
Process Control Document Controls 
Document and Records Purchasing Controls 
Information Management Identification and Traceability 
Occurrence Management Production and Process Controls 
Assessments Acceptance Activities 
Process Improvement Nonconforming Product 
Facilities and Safety Corrective and Preventive Actions 
Service and Satisfaction Labeling and Packaging controls 
 
Handling, Storage, Distribution and 
Installation 
 
Records 
 
Servicing 
 
Step 3: Perform the Initial Assessment  
The next step is an initial laboratory assessment to help laboratory leaders identify areas 
that may lack adherence to regulatory requirements. This assessment will compare current 
laboratory processes and guidance documents to QSE and CFR requirements. In the CFR, required 
documents are denoted by the word shall in the clause. Existing documents should align to those 
required by the QSE and QSR. The initial assessment includes, but is not limited to the descriptions 
in Table 14.  
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Table 14: QSE and QSR requirements 24,41 
 
Quality System 
Requirements 
(QSR) 
CLSI QMS-01 
Quality System 
Essentials (QSE) Activities for Compliance 
Subpart B, Quality 
System 
Requirements 
(CFR) 
Management 
responsibility 
Quality policy Quality planning 
Organization 
Management review 
Quality system 
procedures 
 
  
Quality audits 
 
  
Personnel     
Subpart C, Design 
Controls 
Design controls 
Classification rules Design verification 
Design and 
development planning 
Design validation 
Design input Design transfer 
Design output Design changes 
Design review Design history 
Subpart D, 
Document Controls Document controls 
Document approval 
and distribution 
  
Document changes   
Subpart E, 
Purchasing 
Controls 
Purchasing 
controls 
Evaluation of 
suppliers, contractors, 
and  
  
consultants   
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Purchasing data   
Subpart F, 
Identification and 
Traceability 
Identification     
Traceability 
 
  
Subpart G, 
Production and 
Process Controls 
Production and 
process controls 
Overall requirements Buildings 
Production and process 
change 
Equipment 
Environmental controls Manufacturing material 
Personnel Automated processes 
Contamination control   
Control of inspection, 
measuring, and test 
equipment 
  
Calibration   
Process validation 
Validation 
requirements Review 
effect of process 
changes and revalidate 
Procedures for 
monitoring validated 
processes 
  
 
  
Subpart H, 
Acceptance 
Activities 
Receiving, in-
process, and 
finished device 
acceptance 
General requirements Final acceptance 
activities 
Receiving acceptance 
activities 
Acceptance records 
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In-process acceptance 
activities 
  
Acceptance status     
Subpart I, 
Nonconforming 
Product 
Nonconforming 
product 
Control of 
nonconforming 
product 
  
Nonconforming review 
and disposition 
  
Subpart J, 
Corrective and 
Preventive Action 
Corrective and 
preventive action 
Procedures for 
corrective and 
preventive action 
  
Activities and results 
must be documented 
  
Subpart K, 
Labeling and 
Packaging Control 
Device Labeling 
Label integrity Labeling operations 
Labeling inspection Control number 
Labeling storage   
Device Packaging     
Subpart L, 
Handling, Storage, 
Distribution, and 
Installation 
Handling     
Storage 
Procedures for control 
of storage areas and 
stock rooms 
  
Procedures that 
describe methods that 
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receipt from and 
dispatch to storage and 
stock areas 
Distribution 
Procedures for control 
and distribution of 
finished devices 
  
Distribution records   
Installation 
Installation and 
inspection instructions 
  
Insure proper 
installation, and 
document inspection 
and test results 
  
Subpart M, Records 
General 
requirements 
Confidentiality   
Record retention 
period 
  
Exceptions - what 
records do not need to 
be provided to FDA 
and what can be 
presented instead 
  
Device master 
record 
Device specifications Packaging and labeling 
specifications 
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Production process 
specifications 
Installation, 
maintenance, and 
service procedures 
Quality assurance 
procedures and 
specifications 
 
Device history 
record 
Dates of manufacture Primary identification 
label(s) 
Quantity manufactured Any device 
identification(s) and 
control number(s) used 
Quantity released   
Acceptance records   
Quality system 
record 
Have procedures for 
and maintain complaint 
files 
  
Complaint files 
Review and evaluate 
all complaints 
Maintain records of 
investigations 
 
Investigation of 
complaints relating to 
device failure, labeling, 
or packaging 
Records of 
investigations must be 
reasonably accessible to 
the manufacturing 
establishment 
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Review, evaluation, 
and investigation of 
reportable events 
If complaint unit is 
outside of US, records 
must be accessible with 
the US 
Subpart N, 
Servicing 
Servicing 
Where servicing is a 
requirement, 
procedures are required 
Any service report that 
represents a reportable 
event shall be 
considered a complaint 
and processed 
accordingly 
Analyze service reports Structure of service 
report 
Subpart O, 
Statistical 
Techniques 
Statistical 
techniques 
Where appropriate, 
procedures for valid 
statistical techniques 
  
  
Sampling plans, if 
used, based on valid 
statistical rationale 
  
 
Appendix D. contains an assessment checklist that can be used to document existing laboratory 
processes in comparison to the elements of the standard that may need to be addressed. 
Laboratories may not perform all manufacturing processes described within each specific 
requirement listed in 21 CFR 820. The following exception found in Subpart A, General Provisions 
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Scope provides justification as follows: “if a manufacturer engages in only some operations subject 
to the requirements in this part, and not in others, the manufacturer need only comply with those 
requirements applicable to the operations in which it is engages”. 41 Note: the exclusion of activities 
associated with clauses in the 21 CFR 820 requires rationale to omit and documentation recorded 
in the quality manual. In addition to the operational requirements listed above, the elements 
addressing design, manufacture, testing and approval of LDTs have historically not been included 
in the original 12 QSE.  
The requirements identified in Table 13 and the results of the initial assessment 
documented on the assessment form in Appendix D. will provide insight into the elements needed 
to craft a comprehensive quality framework. The final framework, integrated with QSE and the 
QSR, is depicted in Figure 6.  
 
Figure 6: The 12 QSE integrated with 21 CFR 820 requirements 
 
Step 4: Develop and Implement Policies, Procedures, Processes Identified as Missing During 
Assessment 
 
12 Quality System 
Essentials (QSE)
•Organization
•Customer Service
•Facilities and Safety
•Personnel
•Purchasing & 
Inventory
•Documents & 
Records
•Information 
Management
•Nonconforming 
Events
•Assessments
Continounal 
Improvement
21 CFR 820 Quality 
System Regulation 
(QSR) 
•Adoption of all CFR 
requirements 
applicable to the 
laboratory not 
previously included in 
the 12 QSEs
Design Control 
•Design & 
Development 
•Design input 
•Design output
•Design Review 
•Design Verification
•Design Validation
•Design Transfer
•Design Changes
•Design History
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The process of cross referencing the 12 QSE to the 21 CFR 820 clauses and the results of 
the assessment will provide an accurate determination of policies, procedures and processes still 
required to develop a robust QSR. To comply with regulatory requirements, Table 13. represents 
a high-level guide for the description of activities that must be addressed. For a more 
comprehensive listing see the 21 CFR 820 Standard.41 Any existing documents not meeting 
requirements should be revised and approved using organizational document management 
protocols.  
Step 5: Design Control  
The fifth step includes design of a structure to include all elements of design control not 
previously included in the 12 QSE.  The prior assessment step will determine existing laboratory 
processes that may align with elements of design control.  Figure.7 lists each element of Design 
Control and includes a high-level description for the development of pertinent laboratory guidance 
documents.  The laboratory shall develop of policies, procedures and processes as applied to test 
design to ensure requirements specific to the laboratory are met and proper documentation is 
maintained. Consistent documentation of all tasks and activities throughout each stage of 
development is critical and will capture all changes and modifications as discussed in Design 
history.  
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Figure 7: Elements of Design Control for LDTs (21CFR 820) 29 
 
Step 6: Establishing an Agile Stage Gate Methodology 
To expedite the development of LDTs and ensure all steps are well reviewed and 
documented, the framework may be further established by the use of a product development 
methodology called Agile Stage Gate Hybrid. The agile methodology was initially established for 
the speedy development of new software codes by IT leaders and currently are used in other 
industries with high risk, proliferation costs and limited life cycles such as high tech and product 
development. An Agile product development methodology differs from traditional (PD) due to 
just-in-time internal/external communication and feedback to document and expedite change. The 
traditional Stage Gate technique as described by Cooper (2008) consist of an initiative or project 
(e.g., new product development, software development, process improvement, business change) 
divided into distinct stages or phases, separated by decision points (known as gates). 47  The Stage 
Gate process is described as a macroplanning process that begins with the discovery stage or an 
initial deep understanding of requirements, explained as “camping with the customer”.47  An initial 
planning meeting is held to define regulations, requirements, ideas, and develop the plan with 
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strategic goals and productive outcomes.  A manager is assigned at discovery to validate and move 
the test through each gate to the next stage in development. The project then moves through the 
process of scoping, building a business case, project development, testing, validation and launch 
with a go or no-go decision at each handoff.  
An LDT Launch Executed with Stage Gate Technique 
Comparable to typical product development, the LDT process launch begins with the test 
concept, design and development and the test is classified (Figure 8). Within Stage 2, the design 
input addresses and verifies the intended use of the test and in Stage 3 clinical validity and the 
conformance of the acceptance criteria is confirmed.   The task of Stage 4 is to verify that the 
output of the design requirements meet the input criteria and Stage 5 serves to validate the process 
under defined operating conditions. Stage 6 is the successful transfer of the test design to the live 
laboratory environment; however, each stage does not advance until the go/no go determination is 
made.  The stage gate responsibilities include the following tasks: 1) Inspection at each phase and 
2) Design change, review and history file to document all changes to the process.  
A comprehensive review is conducted at post launch to discuss lessons learned and to identify 
potential challenges for the next launch. This approach to an LDT launch will perpetuate clearly 
communicated processing information, will expedite the process and allow for just-in-time 
response and resolution to meet rapidly changing needs. This technique is credited with increased 
team communication, positive outcomes, just-in-time responsiveness to rapidly changing customer 
requirements and faster product to market.16 
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Figure 8: Agile Stage Gate Hybrid Technique adaptable to LDT development 49  
 
The Application of Agile to Stage Gate  
The agile function within the stage gate technique is considered a microplanning process 
that utilizes a project management (PM) approach within each gate with specific activities and the 
assignment of dedicated cross-functional teams. Cooper and Sommers (2016) describe that the 
most successful applications of agile stage gate hybrid methodology come from organizations that 
assign owners to each gate with the authority to stop the process due to quality concerns.48  The 
dedicated teams manage, maintain and own the launch and are responsible to document details and 
obtain approvals at each gate. In addition, the teams conduct short daily meetings usually 15 
minutes in length to accomplish the following: 1) review accomplishments from the prior day, 2) 
brainstorm resolutions to preexisting discrepancies, 3) prepare for the current day, and 4) review 
team progress from past assignments.  
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  The technique is further divided using “sprints” (short iterations) to develop the project in 
short increments or stages usually from one to four weeks. There are three types of agile stage gate 
hybrid techniques: 
1) Agile and Iterative Development: This type of application is effective when the process is 
consumed with uncertainty, change and speed is crucial to success of the project. 
2) Adaptive or Spiral: This technique employs multiple projects with extended iterations 
when the process is continuously evolving.  
3) Accelerated: This technique is optimal when speed is imperative by adapting the following: 
1) Application of Lean tools such as value stream mapping to identify processes fraught 
with waste and inefficiency and 2) Simultaneous execution to allow multiple projects to 
intersect and advance without the need to remain in one stage until all information has been 
established.48 
Regardless of the agile technique employed, the process requires leadership to direct and own 
the project with the immediate focus on the backlog of issues. The process is iterative and may 
include cyclical projects simultaneously conducted at each step throughout the entire stage gate 
(Figure.9). The team evaluates user needs by brainstorming new solutions and aligns the process 
to accomplish positive outcomes. The new solutions are discussed at the daily or weekly sprint 
meetings and a review is performed to understand lessons learned, successes, failures, assignments 
and what’s next. The cyclical process continues.  
The characteristics of the agile technique for LDT development include:  
▪ Early and continuous customer (FDA) involvement  
▪ An initial comprehensive planning meeting that includes all members of the team 
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▪ Training for leaders and team members in the agile stage gate methodology prior to 
execution  
▪ Empowerment of teams and assignment of responsibility and accountability  
▪ Establishment of the Rules of use: 1) Just in time communication requirements, 2) 
Discussion of progress/failures, and 3) Consistent documentation at every step. 
▪ Continuous learning  
▪ Documentation and follow up of quality issues associated with the LDT process 
 
Figure 9: Agile methodology adapted to LDT development 49 
 
Medical Test Validity  
  The CLIA regulations require laboratories to establish performance characteristics to 
validate the accuracy and precision prior to testing patient samples. (42 CFR 493.1253). 50 Clinical 
and analytical validity should be verified at each step. (Table 15.) 
Table 15: Criteria for Medical Tests 
 
Analytical 
Validity 
“Analytical validity defines the ability of a genetic test to measure accurately 
and reliably the genotype of interest during pre-analytic, analytic and post-
Design	Transfer	Design	Output	 Design	Verification Design	Validation	Design	Input	
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support
Post	launch	
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analytic phases of testing. This part of the evaluation is concerned with assessing 
test performance in the laboratory as opposed to the clinic”. 51 
Does the test measure what we say it measures? 
Clinical 
Validity 
“Accuracy with which a test can predict the presence or absence of the phenotype 
or clinical disease”. 51 
Does the measurement correlate with a clinical situation? 
 
To ensure the clinical validity of a test protocol the following activities and reviews may be 
performed. 17  
1. Linearity Study 
2. Analytical Sensitivity 
3. Precision 
4. Analytical Specificity 
5. Accuracy Comparison of Methods 
6. Reference Intervals/cut off points 
For more information regarding Clinical Validity, see CLIA regulations website. 
Design History 
In the stage gate technique, the team lead or process owner is responsible to follow through, 
resolve issues and document tasks and activities interacted throughout the entire LDT process.   
The illustrative example matrix depicted in Figure.10 can be used as a management tool to 
maintain documentation. 29   
NOTE:  
Link each entry to file with additional information and data.  
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Design History File Traceability Matrix 
Entry	#	 Date User	Needs/Regulation Design	Inputs Design	Verification Design	Validation
1 1/12/16
Secured	Supplier.	
Performed	Supplier	
Qualification.	Ok	to	use	
RD 1/18/16 New	supplier	added	to	list	 RD 1/18/16
Performed		supplier	performance	
and	monitoring.	Supplier	continues	
to	be	accepted.
RD 1/26/16 DC 1/18/16
2 8/16/16 Testing-	allergy	Ag	 RD 1/16/16
Ordered	XYZ	Reagent.	Manufacture	
insert	stated	dilution	is	stable	for	8	
hours
RD 1/16/16
Testing/QC	check	performed	on	
XYZ	reagent	on	8/14/16.	OK	to	use.	
RD 1/18/16 RD	 1/20/16
3 1/12/16 MDR RD 1/18/16 Reportable	error RD 1/18/16 RD 1/26/16 DC 1/18/16
4 8/16/16 Validation	 RD 1/16/16 (IP,	OP,	QP) RD 1/16/16 RD 1/18/16 RD	 1/20/16
Design	History	File	Traceability	Matrix
Reviewed	by/Date
Reviewed	
by/Date
Reviewed	by/DateReviewed	by/Date
Figure 10: A matrix example of required documentation for LDT Design History 
Step Process Task Documentation 
1 QSE Develop a policy, procedure and 
process for each QSE not already 
addressed  
All documents are controlled, 
readily available and the current 
version  
2 21 CFR 820  Develop a policy, procedure and 
process for each clause not 
included in the QSE  
All documents are controlled, 
readily available and the current 
version  
3 Risk  
Classification 
High risk: an incorrect result could to lead to serious consequences for 
the patient. The application for premarket review must be submitted 
prior to offering the test.  
Moderate risk: an incorrect result may lead to the morbidity, mortality 
or may compromise the safety of patients. The laboratory must submit 
validation studies describing accuracy and clinical validity prior to 
offering the tests for premarket review. 
Low risk: an incorrect result or incorrect interpretation is unlikely to 
affect morbidity, mortality or safety of patients. 
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Step 6: Develop the Quality System 
The development of a comprehensive and robust quality management system begins with 
the adoption of the 12 QSE (Step 1) as explained in Table 16.   As stated previously, many 
laboratories are adopting quality management standards, which (if executed to completion) will 
prepare the organization for complying with regulatory requirements. Step 2 addresses the 
establishment of guidance documents for the clauses within the 21 CFR 820 regulatory 
requirements not already included in the 12 QSE. Step 3 describes the process for classifying LDT 
risk--high, moderate or low risk.  Regardless of the risk classification, the support structure of the 
quality management system remains stable. Listed in Step 4 is the development of policies 
processes, and procedures specific to each element of design controls.  When executed 
appropriately these documents will allow for a cascade of verification steps from LDT initiation 
to testing. The series of controlled hand offs will ensure a fail-safe process with quality built into 
every step. Figure. 11 depicts the Stage Gate process that incorporates all elements of the QSR.  
4 Design 
Control  
Develop a policy, procedure and 
process for each clause included in 
the QSR, Design Control 
All documents are controlled, 
readily available and the current 
version  
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Table 16: Steps to Develop a QMS    
 
Figure 11: Design of an Agile Stage Gate Hybrid Regulatory Quality Management System 
Conclusion 
The patient safety concerns identified by the FDA was a turning point in the history of 
laboratories. Whether one is in support of the FDA draft guidance for a QSR in the laboratory, or 
against it, we can all agree that a robust quality management system will provide the structure for 
accuracy and efficacy of LDT design, development and testing, therefore, assuring patient safety.   
The primary constraint of laboratories is the unfamiliarity of the regulatory standard, the meaning 
of design control and the application to laboratory medicine. The challenge becomes the adoption 
of an unfamiliar regulatory requirement and adoption of a formal design control methodology.  
However, after careful review of existing processes the reader may identify some form of the 
requirement already in place, but possibly named differently.  The existing process can be 
expanded to incorporate the requirement and the terminology is irrelevant if the guidance 
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document and process address the regulatory requirement. Documentation of each regulatory task 
and activity along the path of LDT is key to demonstrate compliance. 
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CHAPTER 5. IMPLEMENTING AN AGILE QUALITY MANAGEMENT SYSTEM FOR 
DEVELOPMENT OF LABORATORY DEVELOPED TESTS 
 
 “An accepted framework throughout our industry will set a level playing field as well as provide 
structure, uniformity and integrity to the entire LDT process. ‘” (survey participant) 
Overview  
This chapter assists leaders develop a regulatory QMS structure that is comprised of six stages of 
development. The six stages are as follows: 1) establishment of a leadership support structure, 2) 
training, 3) pre-assessment of current laboratory processes, 4) adoption of design control, 5) 
process controls, 6) process validation and the application of an agile Stage Gate technique for test 
development. 
Introduction 
In 2014, the FDA released a draft guidance for laboratories that develop in-house tests 
entitled Framework for Regulatory Oversight of Laboratory Developed Tests (LDT). 2 In this draft, 
the FDA provides guidance for laboratories that manufacture LDT and explains that enforcement 
discretion once considered optimal for laboratories is no longer appropriate due to the expansion 
of LDT development. The agency acknowledges the current regulatory gap between CLIA and the 
FDA.  Joshua Sharfstein MD, (2015) asserts that these gaps in the present “regulatory system under 
CLIA present a public health risk” and, in response, proposes risk classification, timeframes for 
LDT registration, medical device reporting and a phased approach for implementation of a Quality 
System Regulation (QSR) for laboratories that register LDT for Pre -Market Approval (PMA) or 
510(K) classifications. 3 
Due to differences of opinion within the pathology community, the FDA announced in a 
Discussion Paper dated January 13, 2017 that a final draft guidance would not be issued to allow 
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for additional public discussion and a legislative solution. However, the agency continues to 
support the proposition for regulatory requirements from the 2014 draft guidance and, in a 2017 
Discussion Paper 6, underscores the importance of a (QSR) for the development of LDT that 
includes design controls, acceptance criteria and corrective and preventive action procedures. 
In our initial publication, Facing the Inevitable: Being Prepared for Regulatory 
Requirements for Laboratory Developed Tests, we discuss the prospect of FDA oversight within 
laboratories. 44 We explore adherence to a QSR as proposed by the FDA, because we believe, as 
does Gatter, (2017) that “it is unlikely that the issue is over”. 44,42 We also examine the potential 
implications in the event the FDA gains greater authority over laboratories that develop in house 
laboratory developed tests. Our goal is to understand the regulatory requirements and to consider 
the adoptability of the proposal by laboratories, but more importantly to assess the understanding 
of the community regarding these requirements. The original question that set the path forward for 
this research was the following: Is compliance to the draft guidance possible, and if not, why not 
and what are the constraints? 44 
To gain an understanding and to answer this question, we interviewed nine laboratory 
senior leader professionals with significant knowledge in the field of LDTs. 44 
Their response yielded a significant lack of clarity regarding the FDA draft guidance and 
substantial disparity regarding the meaning of design control as described in 21 CFR 820. In 
addition, we found these leaders struggling to understand how design control could be adapted to 
the diagnostic laboratory since the 21 CFR 820 uses terms relevant to medical devices, not 
laboratories. 1 For the respondents, the intent of the FDA proposal is not fully delineated. The most 
problematic finding from the responses was that the interviewees consider laboratory testing and 
reporting a “service, not a product” and, by extension, not subject to “design control” regulations.  
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Based on the interview results and literature searches, we developed eight strategic factors 
and 40 supporting statements. 44 The strategic factors were tested for functionality, usefulness and 
agility through a survey instrument. We found 35 survey participants in the field of LDT who 
agreed with the eight strategic factors relevant for development of a Quality Management System 
(QMS) regulatory framework. 44 In addition, we collected the top ten supporting statements and 
associated strategic factors from participants considered experts in the field of LDT and developed 
our findings into building blocks for a regulatory quality management system specific to 
laboratories. The collection of this data serves to 1) clarify the needs of laboratories and 2) translate 
the needs into laboratory terms and operational processes otherwise interpreted by the laboratory 
community as applying only to medical device requirements. During the interviews for this initial 
publication, we observed that leaders are taking a wait-and-see approach as opposed to a proactive 
stance, while advice for laboratories from speakers that attended the 2015 FDA Workshop on 
Laboratory Developed Tests Jan 8-9, 2015 is that “laboratories must begin to prepare.” 39, 44    
In a sequel publication, Designing a Quality Management System for Laboratory Developed Tests 
we propose translating the above eight strategic factors and 40 statements into a QMS design for 
LDT oversight that would satisfy the QSR requirements applicable to laboratories. 52 We discuss 
the comparison between the 12 Quality System Essentials as recommended by the Clinical 
Laboratory Standards Institute (CLSI) 9 used by many laboratories to the 21 CFR 820 
requirements. We demonstrate a process to identify and resolve noted gaps between existing 
processes and requirements described in the QSR applicable to addressing LDT development in 
the diagnostic laboratory. 52 
Finally, in this second publication we explain the advantages of an agile stage-gate-hybrid 
product development methodology successful in other industries as a novel approach to expedite 
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LDT development. We illustrate the importance of dedicated cross-functional teams with the 
authority to perform go/no-go approval/rejections at every step and the value in assigning change 
agents and process owners. In conclusion, we suggest the design for a robust quality management 
system framework that follows all pertinent regulations. 52 
In this, our third paper, we illustrate the top ten supporting statements and associated factors chosen 
from experts in the field of LDT, we highlight the findings from participant feedback and we 
demonstrate the translation of those factors into an QMS implementation plan. This 
implementation plan consists of operational processes, which can function as an extension of the 
existing laboratory framework and can be crafted into a regulatory QMS for laboratories. We adopt 
a proven product development methodology successful in other industries and customize it to a 
novel approach for LDT development called Agile Stage Gate Hybrid technique. 47 
The contribution to the literature: We provide the rationale to move away from the wait and see 
approach regarding the adoption of regulatory requirements and we provide an implementation 
guide for a regulatory QMS with structures that support LDT development. We include a novel 
approach to LDT oversight by utilizing the Agile Stage Gate technique adapted to the laboratory 
context which enlists dedicated cross -functional teams to manage and expedite LDT design and 
development. We also suggest the assignment of change agents/process owners with the 
accountability and authority to effect go/no-go approvals at every step. 48 
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Figure 12:  Elements of a quality management system 
 
Prerequisite: A Quality Management System for Laboratories  
A Quality Management System (QMS) is a diagnostic laboratory framework defined as 
“coordinated activities to direct and control an organization with regard to quality”. 37 This 
infrastructure, instituted in many laboratories, consists of the adoption of a set of management 
standards called the 12 Quality System Essentials (QSE) as recommended by the Clinical 
Laboratory Standards Institute (CLSI). 24 This systematic approach to quality considered by the 
World Health Organization as a “path of workflow” begins with the patient and ends with the 
diagnostic result; however, the depth of implementation varies across laboratories. 37 
Consequently, a robust quality structure is only established through the comprehensive 
development of policies, procedures and processes of each element designed at a local, organic 
level. (Figure.12) The QMS elements are as follows: 53  
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Goals of an QMS Implementation Guide 
The goal of this research is to provide guidance for laboratories who wish to extend the 
existing quality management system structure by adopting and incorporating pertinent QSR 
clauses into their operational processes to demonstrate a proactive approach to LTD oversight and 
to assure patient safety.  
Materials and Methods 
As stated earlier in this text, a QMS framework consists of a comprehensive collection of 
policies, procedures and processes that address each management standard. In preparation for this 
implementation guide, we assume that a comprehensive structure consisting of the 12 QSE (Table 
17) has been previously implemented and is currently operational in the laboratory. The method 
for implementing a regulatory QMS is outlined below: 
1) description of the strategic factors and supporting statements identified as extremely important 
for a QMS by experts for LDT development,  
2) translation of pertinent interviewee/survey feedback into pertinent operational processes, and 
3) implementation plan that describes the six phases of development, in sequential steps, and an 
action item checklist. 
Table 17: CLSI’s 12 Quality System Essentials Framework 24 
 
1. Organization 
2. Customer Service 
3. Facilities and Safety 
4. Personnel 
5. Purchasing &Inventory  
6. Equipment  
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7. Process Management 
8. Documents and Records 
9. Information Management 
10. Nonconforming Event Management 
11. Assessments 
12. Continual Improvement 
Using the Strategic Factors as a QMS Development Guide  
The top ten out of 40 strategic factors and supporting statements identified as extremely 
important for a QMS by experts is used as a guide to design, develop, implement and extend the 
existing laboratory framework to a regulatory QMS for LDT development. In addition, the 
interview and survey participant feedback serve as rationale for the development of regulatory 
processes within the implementation plan (all strategic factors and statements from the study are 
listed in Appendix D. Table 18 lists the selected supporting statements paired with eight associated 
strategic factors, interviewee feedback and the resulting implementation plan.  
Table 18: Supporting statements with associated factors chosen by experts for LDT 
development feedback and guidance contributing to implementation plan 
Strategic 
Factors 
Supporting Statements Supporting Feedback Corresponding 
Implementation 
Plan Elements 
      
1.Leadership  
Statement 1: Leadership 
institutes key 
performance indicators 
that outline, measure and 
Leadership provides “buy-
in to review and re-
evaluate whether current 
resources (both personnel 
Top management 
commitment, 
strategic planning, 
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direct regulatory 
initiatives 
and equipment) are 
sufficient to address QMS 
gaps, maintain established 
processes, implement 
change and allow the time 
necessary for the 
implementation of this 
work outside of normal 
duties."44 
 
employee 
empowerment 
Statement 2: Leadership 
commitment to initiate 
and maintain change in 
the organization  
Statement 3: The 
establishment of a QMS 
includes oversight by a 
knowledgeable, educated, 
responsible, informed, 
cohesive team to 
effectively manage the 
process  
Statement 5: Leadership 
consistently 
communicates change 
2. Training Statement 7: The course 
material includes 
regulatory requirements 
and terms and definitions 
in alignment with CLIA 
88, 12 QSEs, 21 CFR 
“Provide laboratories with 
the tools to ensure LDT 
development is conducted 
and documented 
consistently, with the 
demonstration of 
Understanding of 
regulatory 
requirements, terms 
and definitions 
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820/QSR and Design 
Control 
regulatory compliance as a 
by-product.” 44 (survey 
participant) 
3.*Pre-
assessment of 
current QMS 
Not on the list of most 
important 
"I do think that you could 
crosswalk each clause of 
Part 820 to the elements of 
each QSE and use the 
QSEs as the QMS 
framework for LDTs. 
(survey participant) 
 
Development of 
missing policies, 
processes, 
procedures, job 
aids, forms 
QSEQSR 
4.*Design 
Control  
Not on the list of most 
important 
“Design and document 
control is paramount for a 
functional QMS.” 44 
(survey participant). “  
 
Design and 
development: input, 
output, review, 
verification, 
validation, transfer, 
changes, history 
files 
Adverse event 
reporting 
5.Document 
Control 
Statement 25: A 
document control system 
will ensure documents are 
current and are readily 
available 
6.Process 
Control 
Statement 29: Clinical 
validity is performed to 
validate whether the 
“The biggest issue with 
some of the most complex 
LDT's is the clinical 
Clinical validity; 
performance 
characteristics 
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design and optimization 
of the test protocol will 
yield testing outcomes 
that can be used to 
develop a useful clinical 
intervention. 
significance, and how 
results derived from a 
LDT are being used or will 
be used to guide therapy.”  
44 
7.Development 
of a QMS 
Statement 31: The 
primary step to develop a 
regulatory QMS is to 
define a leadership 
support structure with 
defined roles, 
responsibilities, and 
oversight 
"A fully functional QMS 
is needed for a laboratory 
to meet accreditation 
requirements.” 44 
Agile Stage Gate 
Hybrid technique to 
expedite LDT 
development 
8.Process 
validation 
  
Statement 37: A 
validation plan includes: 
Process Qualification, 
(PQ) Operational 
Qualification (OQ), and 
Performance 
Qualification (PFQ) to 
verify that all steps in the 
“Testing an ample number 
of samples to substantiate 
the intended outcome” 44 
(Interviewee # 3) Because, 
validation “is critical to 
ensure the safety of the 
patient and should be 
considered the standard of 
Validation PQ, OQ, 
PFQ 
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Note: The strategic factors 3) pre-assessment of the current QMS and 4) design control was not 
considered extremely important but operationally necessary to identify processes that lack 
adherence to standards. 
Implementation Plan 
The implementation plan includes the following: 
process meet or exceed 
regulatory requirements 
care. ”  44 (Interviewee # 
2). 
 Statement 38: Process 
Qualification (PQ) 
ensures the necessary 
components of the 
process are implemented 
according to design 
specifications. 
Documents necessary for 
operation, performance 
and maintenance are 
verified and the process 
includes all pertinent 
factors 
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Figure 13:  A QMS Implementation Plan consisting of six stages of development 
 
Phase I: Development of the Leadership Support Structure 
A leadership support structure provides the necessary resources to direct the initiative, 
establish leadership oversight at each step throughout LDT development, remove obstacles within 
the path of workflow, and provide ongoing support. Within this leadership structure, sponsorship 
and directives are established, change agents are selected, team leaders are assigned, teams are 
identified and meeting schedules are executed. The establishment of an expeditious pathway from 
LDT development to FDA approval requires the commitment of leadership to own and direct the 
initiative and dedicate the necessary resources to plan, develop, execute and communicate all tasks 
and activities. John Kotter recommends the establishment of a dual operating system that consists 
of traditional leadership to manage the organization and the recruitment of volunteer change agent 
leaders through a “strategy accelerator network.” 54 This network employs volunteer change agents 
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as leaders to dedicate sole responsibility for the initiative and assume the responsibility for 
innovation, change, and strategic initiatives. 54 
In this dual reporting structure, the change agent leadership commits to ensure a quality 
structure that will sustain the initiative and provide ongoing support. In addition, will dedicate the 
time to demonstrate accountability and ensure discrepancies within the flow of work are identified, 
resolved, corrected and documented in real time. The dual reporting structure of leadership support 
includes the following: 
1. Traditional Leadership: Development of a regulatory strategic plan 
a. Development of key performance indicators  
2. Change Agent Leadership: Leadership participation, sponsorship and directives 
a. Outline and measure compliance with regulatory initiatives  
b. Participation and demonstrated support  
c. Assignment of roles and responsibilities to every aspect of the QMS framework: 
i.  The establishment of a QMS includes oversight by a knowledgeable, 
educated, empowered, responsible, informed, cohesive team to effectively 
manage the process.  
3. Change Agent Leadership: Continuously communicates through the establishment of a 
formal structure of change throughout the organization 
Directions: Consider John Kotter’s dual reporting structure to assign a responsible, dedicated 
change agent leader for LDT development: 54 
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Phase II: Training  
The training includes understanding regulatory requirements, applicable terms, and definitions, 
and the importance of documentation throughout the process. In addition, the training program 
includes forming teams for each segment of the LDT process, assigning leaders and emphasizing 
the importance of communication. Luzack, (2012) describes staff training as an essential 
preparatory step in advance of implementation of a QMS because the key to effective 
implementation is a knowledgeable team with an all-encompassing understanding of requirements. 
46 The program outlined includes training modules for the following:  
1. What’s My Role? 
a. Introduction to LDT development, roles and the assignment of roles, responsibility 
of leaders and staff “contributing to the success of the quality system”. 46  
2. Understanding regulatory guidelines 
a. Regulatory requirements and the understanding of terms and definitions for the 
alignment of CLIA 88, 12 QSE, 21 CFR 820/QSR and Design Control  
LEADERSHIP ACTION ITEMS: List the following: 
1. Develop and communicate a strategic plan goal statement 
a. Example: “The organization will develop and adopt a regulatory quality 
management system within the next fiscal year.” 
2. Provide leadership support for creating an LDT structure  
3. Establish communication pathways to ensure continuous communication 
throughout the process 
a. Example:  
4. Form an LDT Oversight Team 
a. Leader  
 
b. Team 
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3. Document Control to comply with Design Control 
a. Document management is the operating control center of a QMS that provide 
direction for staff to perform daily tasks and demonstrate objective evidence that 
the LDT was performed according to policies and procedures. 53 Training for 
document control and record retention at a minimum should include the following: 
i. New document development, review, approval and retention 
ii. Review and approval of changes 
iii.  Documentation/review/approval/retention at every step of LDT 
development 53 
4. Agile Stage Gate Hybrid Technique 
a. The LDT process is clarified using standard project management tools, such as the 
Stage Gate technique. 47 This process allows knowledgeable staff the flexibility to 
expeditiously transport LDT successfully throughout the system, ensuring all 
changes are well-reviewed, documented, and communicated in real time. The 
training modules should include an understanding of the Agile Stage Gate Hybrid 
technique that also include: accountability, ownership for go/no-go decisions at 
each handoff, conducting short daily meetings or huddles and continuous follow-
up to previous tasks.  
Direction: Consider constructing the following for implementation of the training program: 
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Phase III: Pre-Assessment and Development of Policies, Procedures and Processes 
The pre-assessment phase includes a review of policies, processes, and procedures 
within the existing management structure. This is a critical step commonly performed by 
agencies for laboratory accreditation and ISO 15189 programs. The assessment performed 
by these agencies help the laboratory outline the current state and future state of the QMS. 
The adoption of ISO 15189 international standard for medical competence serves as a 
system-wide approach to quality and provides guidance to develop, standardize and share 
a common set of policies, processes, procedures and practices across the entire 
organization. 45 Adoption of ISO 15189 will prepare the organization to reach a level of 
quality more consistent with regulatory requirements. As stated earlier in this text, 
significant variation exists between laboratories; however, laboratory accreditation is on 
the rise in the US, resulting in higher laboratory quality. According to the College of 
American Pathologists (CAP) there are 32 laboratories in the USA that have voluntarily 
earned ISO 15189 accreditation and many pursuing additional quality management 
standards. 13,38   Table 19. consists of reconfigured management requirements organized 
TRAINING ACTION ITEMS: List the following: 
1. Identify subject matter experts to serve as trainers 
 
2. Identify LDT team members who require training  
 
3. List all pertinent organizational guidance documents, regulations and 
specific requirements to be included in training 
a. 21 CFR 820 
4. Develop training modules  
5. Schedule training 
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into similar clauses to demonstrate the commonality and alignment between 12 QSE, 21 
CFR 820 and ISO 15189.  
Table 19: QSE in comparison to the 21 CFR 820 requirements and ISO 15189 requirement 
 
12 Quality System 
Essentials (QSE) 
21 CFR 820 Quality System 
Regulation (QSR) 
ISO 15189:2012 
Organization Management Responsibility Management requirements 
4.1 Organization and management 
responsibility 
4.2 Quality management system 
4.15 Management Review 
Personnel Personnel  
Equipment   
Purchasing and Inventory Purchasing Controls 4.6 External services and supplies 
Process Control Acceptance Activities 
Production and Process 
Controls 
 
Document and Records Document Controls Records 4.3 Document control 
4.13 Control of records 
Information Management 
 
 
Occurrence Management Nonconforming Product 
Corrective and Preventive 
Actions 
4.8 Resolution of complaints 
4.9 Identification and control of 
nonconformities 
4.10 Corrective action 
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4.11 Preventive action 
Assessments Quality Audit 4.14 Evaluation and audits 
Process Improvement  4.12 Continual improvement 
Facilities and Safety 
 
 
Service and Satisfaction Servicing 
 
4.4 Service agreements 
 Handling, Storage, 
Distribution and Installation 
 
  4.7 Advisory services 
  
4.5 Examination by referral 
laboratories 
 Design Controls  
 
  
 Labeling and Packaging 
controls 
 
 
Identification and Traceability  
 
Note: The activities described in some of the 21 CFR 820 clauses have no corresponding 
clauses within other management standards and will require adjustment. 
For a comprehensive description of all tasks and activities associated with each QSR see 
the 21 CFR 820 standard at 21 CFR 820 Standard. 41 
Implementation Step 
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This phase requires assigned personnel to perform a review and to document alignment of 
the management principles from the above standards to existing documents. This step requires the 
review of all applicable requirements, organizational guidance documents and accreditation 
general and technical checklists. The goal of this assessment is to develop a checklist of documents 
that are incomplete or missing. (Table.20) The following is required to perform this step: 
1. Personnel familiar and well versed in laboratory terms and definitions 
2. All applicable guidance documents 
3. Checklist 
Table 20: Example checklist 
 
Checklist Exists Does Not 
Exist 
12 QSE are implemented in the laboratory    
21 CFR 820 activities have been implemented   
Design Control: Identify all activities that do not exist in the 
laboratory 
  
Other regulations   
 
Direction: From the checklist, assign staff to develop the appropriate guidance documents in 
compliance with all requirements. 
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Phase IV: Design Control Translated to Operational Terms 
Design Control comparable to a product development methodology, was originally 
established for the medical device industry and was intended to manage the process of “designing 
purchasing, manufacturing, packaging, labeling, storing, installing and servicing throughout the 
entire product lifecycle. 14 Design control applicable to the laboratory will require the development 
of organic processes translated into policies, processes, procedures that capture all aspects of test 
development with upstream and downstream links specific to each element of design control. The 
potential exists for the laboratory to have established processes that already adhere to one or more 
elements of design control. Design control applicable to the laboratory include documentation of 
changes, review and approval at each step as described in a Design History file. See 21 CFR 820 
QSR for each element of design control. (Appendix C.) 14 
Table 21: Description of each element of design control with suggestions for procedures 
 
PRE-ASSESSMENT AND DOCUMENT CONTROL ACTION ITEMS: Confirm the 
following: 
1. Document all activities implemented to adhere to standard 
Example 
   Process  Alignment Confirmed 
Policy Procedure Process Training 
1. Nonconforming Event X X      X X 
     
     
     
1.       
2.      
3.      
4.      
5.      
6.      
7.      
8.     
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Step  21 CFR 820 
Design Control 
Description 
1 Design and 
Development 
Planning 
Guidance regarding the plan, design, development, execution, 
involvement, interface with different groups and responsibility for 
LDTs. 
2 Design Input Procedure that describes the intended use of the test, user needs and 
the process to manage and resolve discrepancies. The process 
includes responsibility approval, documentation and rationale at 
each step. 
3 Design Output Procedure that describes the output of the design, provides rationale, 
performance, specifications and criteria for verification that the 
design successfully transferred into the testing environment. 
4 Design Review Procedure that describes how all phases of the design will be 
reviewed with documentation and approval at each step. 
Laboratories are required to establish and maintain procedures for 
the identification, documentation, and validation, verification, 
review, and approval of design changes before implementation. 
5 Design 
Verification 
Procedure for determining that the test is safe, effective for use, 
conforms to the needs of the user and meets its intended use. 
Following the procedure ensures the design works as intended and 
has been verified, documented and approved at each activity level. 
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6 Design 
Validation 
Procedure to assure that validation is performed under defined 
operating conditions to ensure the test is appropriate for the 
intended use. 
7 Design Transfer Procedure to describe the accurate transfer of the design into 
manufacturing requirements. 
8 Design Changes Procedure to identify, track, document and approve changes prior to 
each change event. 
9 Design History A means to track processing information pertaining to design, 
development, testing and links with all other design controls to 
demonstrate traceability and approval for each LDT manufactured. 
 
Direction: Review each pertinent element of design control as depicted in Figure 21 and 
identify, develop and implement a guidance document for each topic.  
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Phase V: Process Controls 
Clinical Validity  
Clinical validity defined as the “accuracy with which a test can predict the presence or 
absence of the phenotype or clinical disease” 51 is currently limited to CLIA oversite for analytical 
validation of tests. In addition, the FDA has proposed enforcement for clinical validation of tests 
to include the establishment of the following: 50, 55 
1. Accuracy  
2. Precision 
DESIGN CONTROL ACTION ITEMS: Directions 
For each element of design control as depicted in Figure. 21, develop pertinent guidance 
documents describing LDT activities specific to the processes performed in the lab. 
Example: 
Design Control                     Confirmed 
Policy Procedure Process Training 
Design planning and 
development 
X X X X 
Design input     
Design output     
Design review      
Design verification     
Design validation     
Design transfer     
Design changes     
Design history     
Design transfer     
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3. Reportable ranges 
4. Reference intervals  
5. Interferences 
For more information regarding Clinical Validity see CLIA regulations.  
Directions: To ensure the clinical validity of a test protocol list the pertinent performance 
characteristics and reference ranges for LDT: 
 
Phase VI: Process Validation plan 
To validate the effectiveness of the framework and ensure all tasks and activities meet the 
regulation requirements, a validation protocol is developed to determine if the system is capable 
of managing test variation with fluctuating volume in an agile environment characteristic of LDT. 
A process validation protocol is utilized to ensure the LDT test development framework operates 
as intended. 37 
The validation plan includes: Process Qualification, (PQ) Operational Qualification (OQ), and 
Performance Qualification (PFQ) to verify all steps in the process meet or exceed regulatory 
requirements.  
PROCESS CONTROL ACTION ITEMS: Performance Characteristics 
Performance Characteristics 
 
Reference Range 
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Process Qualification: (PQ) ensures the necessary components of the process are implemented 
according to design specifications. Documents necessary for operation, performance and 
maintenance are identified and the process includes all pertinent factors.  
Operational Qualification: (OQ) will ensure verification, documentation and that the process is 
operating as intended. 
Performance Qualification: (PFQ) demonstrates that the process consistently produces the same 
result and operates correctly when used at defined capacities. Activities included in the PFQ will 
test the entire system within the designed processes of the department, stress the system with a 
documented the response, and ensure that quality checks on tests have been performed. This PFQ 
stage of validation will test the overall process and ensure the system is performing as intended. 
Figure.14 lists all factors suggested for review at each stage:  
The validation items are as follows: 
Process	Qualification	(PQ) Operational	Qualification	(OQ) Performance	Qualification	(PQ)
Item Item Item
Research Design approval Test protocol is complete Quality control checks
Employees are trained Patient/Clinician involvement Reagent QC testing
Equipment maintenance Guidance documents Available supplies/reagents
Polices developed/revised Supplier qualification/performance Process owners
Supplies planned in advance Quality control Discrepancies are noted/resolved
Equipment validation Standardized processes Document control
Design control guidance Design transfer Employees are trained/competent
Origin of an LDT Design changes
Proof of Concept Design history file
Protocol: Design & Development Design validation
Input & output design Equipment validation
Quality control documentation Gaps - regulatory requirements
Equipment validation Gaps in the process
Training records Supervisor oversight
Testing equipment Electronic tracking
Materials / reagents
Supplier Qualification
Regulatory guidelines  
Figure 14: Factors that comprise a validation protocol 
 
Directions: Develop and implement the following: 
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Phase VII. Adoption of an Agile Stage Gate Hybrid Technique for LDT development 
The Agile Stage Gate Hybrid technique is a combination of two common product 
development methodologies that divide activities into stages separated by decision points. Each 
decision point is a go (approval)/no-go (rejection) of each stage. 47 Agile was initially developed 
to expedite software development; however, per Cooper, (2016) the combination of Agile with the 
Stage Gate method of product development has yielded favorable advantages to industries outside 
of software development and this technique has been shown to improve productivity and increase 
speed. 48  
The Agile Stage Gate Hybrid technique begins with strategic directives to plan and execute 
the project as it moves through design, development, testing, validation and launch. An owner is 
assigned to perform the tasks of go/no-go at each step and the process is further managed through 
the assignment of a cross-functional team to document details, to manage the process and to initiate 
a list of missing activities for each project that is rejected at the gate. The process may include 
PROCESS VALIDATION ACTION ITEMS: Validation Protocol 
Confirm implementation of the following Completed: 
Validation plan  
Validation protocol 
a. Process Qualification 
 
b. Operational Qualification  
c. Performance Qualification  
Validation Summary and Approval  
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multiple iterations of projects at each stage.  To confirm that no project is delayed, a daily follow 
up meeting is conducted to review current progress and to review prior commitments for each 
phase which remain incomplete (backlog). 48 A designated team lead is assigned to manage, 
perform and document a comprehensive review at each step and this information is discussed at 
these brief daily meetings. The meetings capture progress, challenges and areas of improvement 
which are then documented on white boards. By clearly communicating requirements, this 
approach to a launch will expedite the process and will allow for just-in-time response, resolution 
and documentation to meet rapidly changing needs. The goal of the meetings is to answer the 
following questions:48   
1. From voice of the customer - what does the internal/external customer value? 
2. What are the deliverables that will address these values within the next phase?  
3. What tasks are needed achieve the desired outcome?  
A post LDT launch review is conducted to discuss lessons learned and to identify potential changes 
for the next launch.  
Applicable to LDT development, the process is reflective of design control beginning with test 
concept and ending with a post launch review. Each phase includes a daily review, discussion of 
the backlog, evaluation of user needs, a sprint (iteration) and back to the daily review as depicted 
in Figure 15. 
The responsibilities include the following: 
1. Leadership oversite and responsibility for the progress of the project and for removing 
barriers  
2. Process owner to stop the process as needed 
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3. Knowledgeable cross functional team as subject matter experts with process responsibility 
and dedicated space to conduct daily meetings 
4. Stage gate go/no-go position performs the following functions: 
a. Inspection/review/documentation at each step 
b. Design change/review/documentation  
c. Design history/review/documentation 
d. Design review/documentation 
 
Figure 15:  Agile Stage Gate Hybrid model for LDT development 
 
Directions: Review and implement the list of items necessary for adoption of an Agile Stage 
Hybrid technique for LDT development.  
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Discussion 
The LDT discussion began when we attempted to answer the question, “is compliance to 
the draft guidance possible, and if not, why not and what are the constraints?” 44 To answer this 
question, we conducted interviews with experts in the field of LDT. We proposed and tested factors 
translated from their responses and concluded the suggested factors were optimal for development 
of a regulatory QMS.  Conversely, the understanding of regulatory requirements, translation of 
those requirements (design control) to operational processes and the assurance of performance 
through process validation were unclear.  44  
The lack of understanding by the laboratory community and the need for a regulatory QMS 
was further supported by Liz Lison, president of Advocea Consulting firm (2015) and a 2015 FDA 
Work Shop speaker that stated, “Most of the failures that I have seen in LDT may have been 
averted if design controls had been in place.” 39 
To assist laboratories, consider the adoption of design control, we provide a support 
structure to define regulatory terms, recognize the current laboratory structure and implement 
missing elements in comparison to the QSR.  Moreover, we suggest a systematic approach to 
implementation of design control through an agile stage gate technique for test development by 
leadership oversite, assignment of owner accountability, teams, sprints and noted responsibility. 
We illustrate a standardized, consistent pathway for LDT development by the delegation of a stage 
gate coordinator tasked to perform design control reviews, changes and documentation of history 
requirements at each stage gate.  
This systematic approach to implementation of a regulatory QMS, will simplify the 
translation of medical device requirements to the diagnostic laboratory.  Once considered 
impracticable and unachievable is now promising through the attainment of knowledge, creativity 
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and the enthusiasm for change. Mahatma Gandhi reminds us “we need not wait to see what others 
do” but, to be the change we want to see in the world.  That will require moving past the status 
quo as seen in many laboratories today as this is the way we have always done things to how can 
we improve the process that will ultimately ensure patient safety?  
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CHAPTER 6: CONCLUSION & DIRECTIONS FOR FUTURE RESEARCH 
Conclusion 
The impetus for change within the laboratory environment began with the awareness of 
patients adversely affected by outcomes associated with Laboratory Developed Tests. 
Consequently, the design, development and manufacture of LDTs is not under the jurisdiction of 
CLIA and testing operations is not formally within the oversight of the FDA.  
The interviews with nine expert senior professional leaders within in the field of LDT 
across regulatory, laboratory, accreditation and medical device industries served as the authority 
based on their stature and established the consensus for the response of topics discussed. Many 
interviewees claim the laboratories offer a “service, not a medical device” and furthermore, the 
FDA has no jurisdiction over LDT. 1 However, before proposed legislation can occur the agencies 
must bridge the gap between required regulations. Shelia Walcoff of Goldbug Strategies (2015) 
and a FDA Work Shop speaker stated that “It is essential that FDA harmonize the QSR 
requirements with CLIA requirements at a more granular level to prevent duplicate efforts and to 
ease the regulatory burden” because governmental agencies have not provided the necessary 
guidance for struggling laboratories.” 39  
The interviewees shared this concern for CLIA and the FDA, however, before legislation 
can occur the agencies must collectively develop standards and guidance documents prior to a 
policy release because laboratories are misguided and unclear how FDA regulations translate to 
the laboratory. The adoption of a quality system regulation to ensure accurate test development 
appears incomprehensible under current laboratory operating structure. The lack of standards has 
resulted in fluctuating levels of quality within laboratories and implementation of process 
standardization and 12 Quality system essentials is based on the support of leaders to own and 
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drive an organic, directed initiatives with tasks and activities applied to local specific 
organizational processes. 53   A call for action has been initiated to promote proactive leadership 
commitment to prepare laboratories for the inevitable.  
Moreover, the current FDA regulations 21 CFR 820 are developed for medical device and 
translation to operational laboratory terms does not exist.  As a result, laboratories are taking the 
wait and see approach and have not registered their tests with the FDA, meanwhile, the FDA 
continues to understand the testing needs of the laboratories.  The absence of test registration 
creates the inability of the regulatory agencies to create a standard reporting structure; without a 
standard reporting structure, laboratories continue to struggle to understand how these proposed 
changes will affect current operations. Gatter, (2017) has stated “it is unlikely that the issue is over 
“.42   In fact, in the January 13, 2017 discussion paper the FDA indicates support for CLIA 
requirements regardless of the dissimilarity to 21 CFR 820 Quality System Regulation 
requirements and continues to recommend a QSR “consistent with the approach described in the 
discussion paper” for FDA requirements not mandated by CLIA. 6 
In support of the FDA Discussion paper, the survey respondents agreed that a regulatory 
oriented framework for the development of LDTs is needed in the laboratory.  This was 
substantiated by results of exploratory research that included responses from 51 survey 
respondents out of a population of 767 attendees at the Executive War College Laboratory 
Conference in New Orleans, May 2016. Although the survey was sent to a large population of 
conference attendees the population included leaders within all areas of the laboratory including:  
sales, diagnostic imaging, medical device, diagnostic laboratories, reimbursement firms and many 
others.  Moreover, the field of LDT is a small niche market so the response rate of 51 survey 
participants was a result of actual attendees that claimed to be experts in the field of LDT.  
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It was interesting to note that the survey respondents as experts in the field of LDT did not consider 
design control as extremely or very important despite the proposal for a QSR by the FDA. In 
addition, the eight suggested strategic factors and 40 statements derived from the literature, 
interviews and the FDA work shop provided the impetus for design of an QMS regulatory 
framework.  
The respondents agreed with all statements relevant to the design of a QMS based on needs 
and gaps expressed by laboratory professionals. This finding aligns with the results of the survey 
as there was no significant difference in the way the experts verse non- experts responded to factors 
and associated statements. All respondents chose most statements as 1) extremely important or 2) 
very important.  This finding aligns with the recommendation by Katherine Tynan, an independent 
regulatory consultant from the 2015 FDA workshop that offered advice to governmental agencies 
as follows: 
4. “Develop a common vocabulary that laboratories can understand” 
5. “Simplified the cumbersome QSR and assist laboratories translate the directives”  
6. “Develop a “QSR fit for purpose and harmonize the standard” 
Katherine’s advice to laboratories was to “invest in a quality management system, implement all 
factors of design control, and be proactive and prepare for future regulatory requirements.” 39 
Consequently, the interviewees agreed that the terms, expectation and current recommendations 
lack user definition, specific methods for testing protocols, and clear testing requirements. The 
preparation of a QMS require the understanding where gaps exist to develop appropriate processes 
that would to adhere to requirements, however, the survey statement suggesting review of current 
policies and procedures to identify gaps was not considered important by all groups. This was an 
interesting conclusion, since this is general practice within laboratory accreditation agencies.   
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A process to incorporate the accreditation and regulatory standards has been customized 
from product development to test development for the diagnostic laboratory. The agile stage gate 
hybrid technique incorporates design control with the assignment of process owners, cross 
functional teams, and a stage gate coordinator to perform review, changes and history tasks and 
activities. 
Resolution of Research Questions  
The research question 1: Can laboratories operationalize a quality management framework 
that will meet FDA requirements?  The preparation of a QMS necessitates laboratory leadership 
to understand the proposal by the FDA regarding all facets of LDT, take the initiative and provide 
the appropriate resources to bridge the gap from an accreditation focused operating structure to a 
regulatory framework.  The survey participants concurred that the most favorable factors to design 
and implement a regulatory QMS consist of tasks and activities associated with the following 
categories: 1) Leadership, training, pre- assessment, 2) design control, 3) document control, 4) 
process control, 5) development of a QMS framework and 6) process validation. The test 
development process is then navigated through the agile stage gate hybrid technique to expedite 
test development to satisfy the supply chain of service, process and people. 
Research question number 2: Will an adoption of a quality system framework provide the 
manufacturing foundation that will adhere to 21 CFR 820 Design Controls?  
The manufacturing foundation built from the strategic factors discussed above is expanded 
to include tasks and activities within each element of design control. This customized product 
development methodology translated from medical device to the laboratory testing environment is 
further expanded by utilization of the agile stage gate hybrid technique for LDT launch. The 
technique is customized by the establishment of laboratory leads as owners that contain the 
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authority to reject and stop the process due to quality concerns. In addition, the role of stage gate 
coordinator was established as an objective position to perform review at each gate and document 
changes and history throughout test development.  
Directions for Future Research  
The future research in the field of LDT can be pursued along four areas: 1) Live pilots for 
the development of a regulatory QMS for in-house LDTs, 2) Product development methodology 
adaptable to the laboratory, 3) Implication of venture capitalist funding/support for or against LDT 
development, and 4) Enhancement of current regulations for the adoption, clarification and 
registration of tests for risk assessment.  
1) I plan to be involved with a pilot to be conducted in a live environment at the Department of 
Defense in Washington DC. The goal of this pilot is to demonstrate and substantiate outcome 
measures, lessons learned and the feasibility to move laboratories from the status quo to a system 
designed for patient safety. This approach will require proactive leadership, resources, creativity 
and innovation and may be considered the most significant step towards diffusion since 
development of the Laboratory Improvement Amendment Act (CLIA) under the Centers for 
Medicare and Medicaid Services (CMS) in 1967, 1988. 4 The live pilot in the laboratory will 
investigate the need for “tailored” framework developed for the LDT community based on test 
complexity, risk, and volume. 
2) Another area for future research is the adoption of a product development methodology to the 
laboratory environment to address risk management, test allocation, planning and implications of 
limited resources across a portfolio management approach to LDT development with the 
opportunity to explore share resources and components for similar tests access multiple 
laboratories. 
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3) Another line of extension for future research would be to investigate the influence of venture 
capital (VC) funding for LDT development. While VC funds would be interested in quicker and 
larger returns on investment (ROI), they would also be concerned about adverse health risk 
events associated with the tests. It would be interesting to investigate whether this would require 
any modifications to the proposed QMS framework. 
4)  Establishment of technical requirements associated with clinical validity, performance 
characteristics or risk classification addressed in more detail by the CLIA under the Centers or 
Medicare and Medicaid. 
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APPENDIX A. E-MAIL INVITE FOR INTERVIEW 
Good afternoon, 
My name is Rita D'Angelo, the former Quality Manager from Henry Ford Health System, 
Pathology and Laboratory Medicine in Detroit, Michigan. 
I am currently working on my Ph.D. dissertation and I'm seeking an understanding and 
clarification on the regulatory perspective of Laboratory Developed Tests.  
Are you available for a 30-minute phone interview to answer a few questions regarding the position 
of CAP accreditation/CLIA, FDA and the future implication for laboratories? 
Thank you for your assistance and participation. 
Warm regards, 
Rita D’Angelo 
PHD Candidate  
Wayne State University 
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APPENDIX B. INTERVIEW PROTOCOL- LABORATORY DEVELOPED TESTS 
Date: ___________________ 
Interviewer initials:  Time frame of Interview:  
Interviewee initials:  Location:  
Event # Recording # 
 
Introduction 
Hello, my name is Rita D’Angelo and I am a student of Wayne State University working towards 
my Ph.D. dissertation. I am conducting research to learn about the process of Laboratory 
Developed Testing (LDT protocols within medical laboratories.  I would like to understand more 
about this topic from the perspective of governmental policy, challenges of Laboratory leadership 
and potential process changes. I sincerely appreciate your assistance and making the time available 
for me to ask you some questions.  
The goal of this interview is to learn your perspective, understanding and outlook on Laboratory 
Developed Tests as it relates to the overarching federal requirements and future strategy. I 
encourage you to be as open and candid with me as possible and I pledge to keep your responses 
confidential.  I will interview many staff members that have a direct responsibility, oversight or 
outcome associated with Laboratory Developed Tests. I am searching for strategy, future direction 
and process related information across the interviews. I will compile findings and summarize the 
results without identifying anyone specifically. 
Do I have your permission to record this interview? This will allow me to time to document and 
verify the accuracy of my notes.  Recordings will not be shared with anyone and will be destroyed 
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at the conclusion of our project. Please feel free at any time to ask me to stop the recorder if you 
want to say something or alert me if you do not wish to be recorded.  Can I proceed?  
Feel free to ask any questions before we begin.  
1. What is your role and responsibility in the organization? 
a. What is your title? 
2. Tell me about the history and your knowledge about of Lab developed Tests? 
3. What are some of the regulatory challenges associated with LDT’s? 
4. How does genetic testing influence regulatory oversight? 
5. Describe the current scrutiny associated with regulatory guidelines for LDT’s? 
6. What is the role of the FDA in lab developed tests? 
7. Explain the intent of the FDA guidance framework for LDT’s released December 2014? 
8. In your opinion, what would the implications(s) be if the FDA mandated regulatory 
guidelines for the process of LDT’s? 
9. How would you describe the “outcome and view of the future” if the FDA mandates 
regulatory oversight for LDT’s?  
Thank you for your time and attention. This is the conclusion of the interview. Please do not share 
these questions with anyone. 
If you think of anything else that you would like to share or if you know someone else that would 
be beneficial in this process, feel free to contact me by e-mail or phone. All interactions, 
information and conversations are maintained as confidential.  
Thank you! 
Follow-up-Name:  Date of Follow-up; 
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Next meeting-Name: Date of Next Meeting: 
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APPENDIX C. DESIGN CONTROL 
General. (1) Each manufacturer of any class III or class II device, and the class I devices listed 
in paragraph (a)(2) of this section, shall establish and maintain procedures to control the design 
of the device in order to ensure that specified design requirements are met.  
(b) Design and development planning. Each manufacturer shall establish and maintain plans 
that describe or reference the design and development activities and define responsibility for 
implementation. The plans shall identify and describe the interfaces with different groups or 
activities that provide, or result in, input to the design and development process. The plans 
shall be reviewed, updated, and approved as design and development evolves.  
(c) Design input. Each manufacturer shall establish and maintain procedures to ensure that the 
design requirements relating to a device are appropriate and address the intended use of the 
device, including the needs of the user and patient. The procedures shall include a mechanism 
for addressing incomplete, ambiguous, or conflicting requirements. The design input 
requirements shall be documented and shall be reviewed and approved by a designated 
individual(s). The approval, including the date and signature of the individual(s) approving the 
requirements, shall be documented.  
(d) Design output. Each manufacturer shall establish and maintain procedures for defining and 
documenting design output in terms that allow an adequate evaluation of conformance to 
design input requirements. Design output procedures shall contain or make reference to 
acceptance criteria and shall ensure that those design outputs that are essential for the proper 
functioning of the device are identified. Design output shall be documented, reviewed, and 
approved before release. The approval, including the date and signature of the individual(s) 
approving the output, shall be documented.  
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(e) Design review. Each manufacturer shall establish and maintain procedures to ensure that 
formal documented reviews of the design results are planned and conducted at appropriate 
stages of the device's design development. The procedures shall ensure that participants at each 
design review include representatives of all functions concerned with the design stage being 
reviewed and an individual(s) who does not have direct responsibility for the design stage 
being reviewed, as well as any specialists needed. The results of a design review, including 
identification of the design, the date, and the individual(s) performing the review, shall be 
documented in the design history file (the DHF). (f) Design verification. Each manufacturer 
shall establish and maintain procedures for verifying the device design. Design verification 
shall confirm that the design output meets the design input requirements. The results of the 
design verification, including identification of the design, method(s), the date, and the 
individual(s) performing the verification, shall be documented in the DHF.  
(g) Design validation. Each manufacturer shall establish and maintain procedures for 
validating the device design. Design validation shall be performed under defined operating 
conditions on initial production units, lots, or batches, or their equivalents. Design validation 
shall ensure that devices conform to defined user needs and intended uses and shall include 
testing of production units under actual or simulated use conditions. Design validation shall 
include software validation and risk analysis, where appropriate. The results of the design 
validation, including identification of the design, method(s), the date, and the individual(s) 
performing the validation, shall be documented in the DHF.  
(h) Design transfer. Each manufacturer shall establish and maintain procedures to ensure that 
the device design is correctly translated into production specifications.  
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(i) Design changes. Each manufacturer shall establish and maintain procedures for the 
identification, documentation, and validation or where appropriate verification, review, and 
approval of design changes before their implementation. (j) Design history file. Each 
manufacturer shall establish and maintain a DHF for each type of device. The DHF shall 
contain or reference the records necessary to demonstrate that the design was developed in 
accordance with the approved design plan and the requirements of this part.  
Source: 21 CFR 820, Design Controls, FDA (2014) 
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APPENDIX D. LABORATORY ASSESSEMENT WORKSHEET 
Assessment Statement  
Exists 
 
Does Not 
Exist 
1. All 12 QSE are implemented in the laboratory    
2. List missing QSE   
3. QSE comply with QSR   
4. Identify all outliers    
5. All 21 CFR 820 activities have been implemented   
6. Design Control: Identify all activities that do not exist in the 
laboratory 
  
7. All elements of design control have been implemented   
8. There is documentation for research and development of test 
design and service development.  
       
9. Responsibility for design and development activities are 
defined  
       
10. Design input, review and output activities are defined.        
11. Documentation exists for design and history of change.       
12. There is documentation for design transfer to testing 
parameters 
       
13. Documentation exists for initiation of LDT       
14. Logistics are in place to support the supply chain        
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15. A process in place to secure appropriate supplies and 
reagents 
      
16. There are procedures and processes for supplier qualification        
17. There a process for supplier performance and monitoring        
18. Design control elements are applied        
19. There is validation plans for equipment and processes        
20. Customer supplier interaction exists throughout the lifecycle 
to resolve discrepancies and documentation maintained 
      
21. Quality control performed for all testing and records are 
maintained 
      
22. A standard format exists for result reporting         
23. Policies, procedures or processes    
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APPENDIX E. QUALTRICS SURVEY RESULTS: MANAGEMENT CATEGORIES AND 
40 STATEMENTS 
Q1: Leadership 
Statement 1: Leadership institutes key performance indicators that outline, measure and direct 
regulatory initiatives 
Statement 2: Leadership commitment to initiate and maintain change in the organization 
Statement 3: The establishment of a QMS includes oversight by a knowledgeable, educated, 
responsible, informed, cohesive team to effectively manage the process 
Statement 4: Establishment of an LDT quality committee to quickly approve changes and provide 
support 
Statement 5: Leadership consistently communicates change 
Q2: Training 
Statement 6: The training program includes a basic introduction to the manufacture of LDTs and 
the roles and responsibility of leaders and staff 
Statement 7: The course material includes regulatory requirements and terms and definitions in 
alignment with CLIA 88, 12 QSEs, 21 CFR 820/Q SR and Design Control 
Statement 8: The program includes value stream mapping to demonstrate the significance of 
hand- offs, tasks and activities and all aspects of the LDT process beginning with research and 
development and ending with diagnostic testing  
Statement 9: Staff training includes the process of successfully navigating the LDTs through the 
system to ensure all changes are well reviewed, documented and communicated 
Statement 10: The assignment of responsible persons(s) to address, resolve, communicate and 
document testing concerns 
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Q3: Pre- assessment  
Statement 11: The review of existing laboratory processes in comparison to the list of 12 QSE 
management principles will identify policies, procedures or processes not previously addressed 
Statement 12: Quality management standards, such as ISO 15189 if executed to completion will 
better prepare the organization to comply with regulatory requirements 
Statement 13: A cross walk of current processes in comparison to 21 CFR 820 quality system 
regulation will assist laboratory leaders identify and understand pertinent gaps in the QMS 
Statement 14: A pre- assessment of existing policies, procedures and processes may reveal 
informal processes or documents not previously considered compliance to a regulatory 
requirement 
Statement 15: A clear understanding the QSR requirements is key to implementing processes for 
a robust quality management system 
Q4: Design Control 
Statement 16: Implementation of all aspects of design control including design, development, 
input, output, review, verification, transfer, changes and history will demonstrate adherence to 
regulatory requirements and patient safety 
Statement 17: Design control described in laboratory terms will clarify the requirements for 
translation and adaptability to the laboratory environment 
Statement 18: Design control well implemented and documented will ensure quality is built into 
every step 
Statement 19: The translation of 21 CFR 820 requirements into laboratory terms will highlight 
and address the content required for the development of standard operating procedures  
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Statement 20: A procedure that address the process for identification, documentation and 
reporting of an adverse event is referred to as medical device reporting 
Q5: Document Control 
Statement 21: Updated and accurate standard operating procedures serves as verification of 
compliance 
Statement 22: A clearly written procedure for each phase of test development will remove any 
ambiguity in the process 
Statement 23: Record retention and timely retrieval of documentation related to the design, 
manufacture and testing of LDTs demonstrated regulatory compliance 
Statement 24: Documentation of tasks and activities at each step of the test development process 
is captured, reviewed and approved to address the design history requirement 
Statement 25: A document control system will ensure documents are current and are readily 
available 
Q6: Process Control 
Statement 26: The process of LDT manufacture include assigned tasks and responsibility at every 
hand- off to ensure concerns are identified, resolved, documented and communicated   
Statement 27: The consistent uninterrupted flow of material, product, and information between 
handoffs is critical to demonstrate the user friendliness of the framework 
Statement 28: Documentation of analytical validity will demonstrate and document the accuracy 
and reliability of test performance 
Statement 29: Clinical validity is performed to validate whether the design and optimization of 
the test protocol will yield testing outcomes that can be used to develop a useful clinical 
intervention 
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Statement 30: Data collection and clearly communicating requirements in an LDT launch will 
expedite the process and will allow for just-in-time response and resolution to meet rapidly 
changing needs 
Q7: Development of a QMS Framework 
Statement 31: The primary step to develop a regulatory QMS is to define a leadership support 
structure with defined roles, responsibilities and oversight 
Statement 32: Employee training describes terms definitions and regulatory requirements for the 
development, manufacture and testing of LDTs 
Statement 33: Performance of a cross walk or pre- assessment to detect all aspects of the current 
QMS in comparison to CLSI and QSR requirements 
Statement 34: Review the pre- assessment findings and create a list of necessary guidance 
documents in need of development 
Statement 35: Develop missing policies, procedures and processes to comply with regulatory 
requirements 
Q8: Process Validation 
Statement 36: Process validation is performed to ensure effectiveness of the framework 
Statement 37: A validation plan includes Process Qualification(PQ), Operational 
Qualification(OP) and Performance Qualification(PFQ) to verify that all steps in the process meet 
or exceed regulatory requirements 
Statement 38: Process Qualification (PQ) ensures the necessary components of the process are 
implemented according to design specifications. Documents necessary for operation, performance 
and maintenance are verified and the process includes all pertinent factors. 
Statement 39: Operational Qualification will ensure the process is operating as intended  
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Statement 40: Performance qualification (PFQ) demonstrates the process consistently produces 
the same result and operates correctly when used at defines capacities. 
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APPENDIX F. INTERVIEW RESULTS 
Interview Topic # 1: Risk Classification 
The most critical ambiguity mentioned ten times within all nine interviewees was the inability to 
identify testing categories into high, moderate or low classifications and the process of LDT 
registration. There is no current LDT approval process in place and very “few laboratories have 
registered their LDT with the FDA.” (Interviewee # 7) Because very few laboratories have taken 
this proactive step no “precedent has been set” (Interviewee # 7) making the test approval process 
daunting at best.  Despite the lack of clarity by the FDA, New York State (NYS) has currently 
mandated all laboratories that develop LDTs to register their tests and classify their risk as of 
November 14, 2016.3 
Interview Topic # 2: Validation of Test Systems 
Another common theme among the participants was the accuracy of test development and 
validation to ensure patient safety.  Interviewees emphasized the importance of systems to validate 
protocols, processes and test development that will consistently ensure the effectiveness and 
accuracy of test results. All interviewees shared a common concern regarding the effectiveness of 
test validation and future requirements to formally “test an ample number of samples to 
substantiate the intended outcome” (Interviewee # 3).  
Interview Topic # 3: Uncertainty Over Future LDT Mandates 
There was significant trepidation expressed by all interviewees regarding the uncertain future of 
FDA mandates over every aspect of the LDT process. The participants expressed concern and 
ambiguity regarding the draft guidance and its consequences should it become final policy.  For 
example, if the FDA mandates clinical trials for the development of high-risk tests, as required for 
medical devices, many smaller laboratories without adequate resources may find it necessary to 
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outsource their LDTs, discontinue them, or partner with larger laboratories. This concern is 
substantiated by Klein,( 2016) who states that significant financial consequences exist for 
laboratories and that the proposal as written could cause discontinuance of many LDTs.12  Larger 
laboratories, including reference laboratories, have a competitive edge over smaller labs, including 
the utilization of advanced genetic testing technology like Next Generation sequencing. This 
technology generates enormous amounts of disease-related data in real time, and in support of 
LDT development and validation.  
Interview Topic #4: Patient Safety Measures of Accuracy and Efficacy  
Eight participants expressed concerns that the lack of regulatory oversight for LDTs may have led 
to adverse patient safety outcomes such as the misdiagnosis of serious illness as a result of 
inaccuracies of testing protocols and their results.  Additionally, patients may have been treated 
for disease they did not have, or did not receive treatment for diseases they did have. The common 
sentiment expressed during these interviews was of the need for thoughtful consideration of the 
accuracy of test development, safe-testing practices, test verification and reproducibility of results.  
The interviewees described their concern for accurate testing outcomes and process validation. 
One participant stated that process validation “is critical to ensure the safety of the patient and 
should be considered the standard of care” (Interviewee # 2). 
Interview Topic # 5: Adopting a Quality System Regulation Framework 
Six participants discussed their concern for laboratories being able to adopt this framework and 
raise the level of quality within their organizations. They shared a common response that 
laboratories lacked the rigor that is required for the manufacture of medical devices, and that could 
translate to LDT development.  Change is necessary in order to raise the level of quality, prioritize 
tasks and dedicate the time and resources necessary to understand regulatory requirements in order 
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to attain process standardization. Ambiguity existed during the interviews regarding the definition 
of design control and how to appropriately address these requirements. As reinforcement of this, 
Liz Lison, president of Advocea Consulting firm and a conference speaker at the 2015 FDA 
Workshop on Laboratory Developed Tests explained, “Most of the failures that I have seen in 
LDTs may have been averted if design controls had been in place. Therefore, I urge the agency 
not to delay the enforcement of design controls for high-risk tests and potentially introduce a two 
-tier system for pre-market review”.13 
Interview Topic # 6: Accreditation  
Six participants stated that the FDA lacks the resources necessary to inspect all labs across the 
USA and would eventually require the assistance from third party accreditation agencies.  As stated 
in their 2017 Discussion Paper, the FDA explains, “expansion of inspection will include a “third 
party inspection program for LDTs so that many of these post-market inspections could be 
conducted by FDA-accredited third parties. This would allow such third parties, when appropriate, 
to inspect for the three additional FDA QS requirements at the time of a routine CLIA survey 
inspection.”14  The FDA appears to be working towards this by exploring opportunities to 
coordinate with and leverage existing programs such New York and other programs managed by 
organizations approved by CLIA.14 
Interview Topic #7:  Quality Management System 
Four interviewees indicated that in the absence of a policy and a defined set of standards, 
laboratories will likely take the wait and see approach, not progressing with change or development 
until required.  Because “development of a quality structure takes a considerable amount of time” 
(Interviewee #3), laboratories should consider whether to prepare in anticipation of regulatory 
changes. In the face of uncertainty over how 21 CFR 820 requirements applies to laboratory testing 
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services, laboratory leaders need greater clarity on understanding and preparing for a QSR 
framework. Katherine Tynan, an independent regulatory consultant at the 2015 FDA Work shop 
on Laboratory Developed Tests, expressed her concerns and offered advice to governmental 
agencies as follows: 13 
• “Develop a common vocabulary that laboratories can understand” 
• “Simplified the cumbersome QSR and assist laboratories translate the directives”  
• “Develop a “QSR fit for purpose and harmonize the standard” 
Her advice to laboratories was to “invest in a quality management system, implement all factors 
of design control, and be proactive and prepare for future regulatory requirements.”13  However, 
laboratories lack guidance and direction and the current historical documents refer to medical 
device, rather than laboratories.  Translation of the requirements to practical laboratory language 
is not easy, and the resources required for development of a structure to comply with regulatory 
requirements is difficult to estimate. 
The Clinical Laboratory Improvement Act has not updated the original laboratory standard since 
1988.  Four interviewees expressed the need for CMS and the FDA to reach an understanding 
regarding requirements and aim towards consistency of purpose prior to a policy release.  Shelia 
Walcoff of Goldbug Strategies at the 2015 FDA Work shop on Laboratory Developed Tests stated, 
“It is essential that FDA harmonize the QSR requirements with CLIA requirements at a more 
granular level to prevent duplicate efforts and to ease the regulatory burden, because governmental 
agencies have not provided the necessary guidance for struggling laboratories.” 13 The FDA 2017 
Discussion Paper addresses this concern by the following statement “Adapting CLIA to enable 
CMS to provide the kind of effective oversight of LDTs that is needed to ensure that they are 
accurate, reliable, and clinically valid would require a significant change in the nature of what the 
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agency does, rather than minor modifications as some have suggested. By its very nature, a CMS-
only framework for LDTs could create costly federal redundancies and inefficiencies.” 13 The 
oversight of laboratory testing remains with CMS (and CLIA), however, a gap exists regarding the 
regulation of test development. Due to the advances in genomic medicine the oversight by CLIA 
is no longer adequate to manage the compliance needs of laboratories. This is highlighted by the 
significant difference in the oversight between FDA and CLIA.  The FDA does not mandate the 
operations of testing as stated in 21 CFR 820, while CLIA does not ensure the safety and 
effectiveness of test protocols as described in CFR 493.  As stated by Interviewee # 1, “there are 
no plans for CLIA to update policies at this time.”  
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APPENDIX G:  SURVEY RESULTS: TOP TEN RESPONSES BY EXPERTS PER 
SIGNIFICANCE OF MEANS 
 
1. Leadership: Statement 1: Leadership institutes key performance indicators that outline, 
measure and direct regulatory initiatives 
2. Leadership: Statement 2: Leadership commitment to initiate and maintain change in the 
organization 
3. Leadership- Statement 3: The establishment of a QMS includes oversight by a 
knowledgeable, educated, responsible, informed, cohesive team to effectively manage the 
process 
4. Leadership: Statement 5: Leadership consistently communicates change 
5. Process Control: Statement 29: Clinical validity is performed to validate whether the 
design and optimization of the test protocol will yield testing outcomes that can be used to 
develop a useful clinical intervention. 
6. Process Validation: Statement 37: A validation plan includes: Process Qualification, 
(PQ) Operational Qualification (OQ), and Performance Qualification (PFQ) to verify that 
all steps in the process meet or exceed regulatory requirements  
7. Process validation: Statement 38: Process Qualification: (PQ) ensures the necessary 
components of the process are implemented according to design specifications. Documents 
necessary for operation, performance and maintenance are verified and the process 
includes all pertinent factors 
8. Development of a QMS Framework: Statement 31-  The primary step to develop a 
regulatory QMS is to define a leadership support structure with defined roles, 
responsibilities, and oversight 
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9. Training- Statement 7: The course material includes regulatory requirements and terms 
and definitions in alignment with CLIA 88, 12 QSEs, 21 CFR 820/QSR and Design Control 
10. Document Control -Statement 25: A document control system will ensure documents are 
current and are readily available  
The MOST important responses by ALL groups per significance of means 
1. Leadership: Statement 2: Leadership commitment to initiate and maintain change in the 
organization 
2. Leadership Statement 5: Leadership consistently communicates change  
3. Leadership Statement 1: Leadership institutes key performance indicators that outline, 
measure and direct regulatory initiatives  
4. Leadership Statement 3: The establishment of a QMS includes oversight by a 
knowledgeable, educated, responsible, informed, cohesive team to effectively manage the 
process 
5. Process Control: Statement 29: Clinical validity is performed to validate whether the 
design and optimization of the test protocol will yield testing outcomes that can be used to 
develop a useful clinical intervention  
6. Pre-Assessment of Existing QMS: Statement 15: A clear understanding of the QSR 
requirements is key to implementing processes for a robust regulatory quality management 
system  
7. Process Validation Statement 37: A validation plan includes: Process Qualification, (PQ) 
Operational Qualification (OQ), and Performance Qualification (PFQ) to verify that all 
steps in the process meet or exceed regulatory requirements 
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8. Document Control Statement 25: A document control system will ensure documents are 
current and are readily available  
9. Process Control Statement 28: Documentation of analytical validity will demonstrate and 
document the accuracy and reliability of test performance   
LEAST important responses by ALL groups per significance of means  
1. Development of a QMS Framework: Statement 32: Employee training describes terms, 
definitions and regulatory requirements for the development, manufacture and testing of 
LDTs 
2. Development of a QMS Framework: Statement 34: Review the pre- assessment findings 
and create a list of necessary guidance documents in need of development in comparison 
to 21 CFR 820 Quality System Regulation will assist laboratory leaders identify and 
understand pertinent gaps in the QMS 
3. Pre-assessment of Existing Quality Management System 
a. Statement 14: A pre- assessment of existing policies, procedures and processes 
may reveal informal processes or documents not previously considered compliance 
to regulatory requirements 
b. Statement 11: The review of existing laboratory processes in comparison to the 
list of CLSI 12 QSE management principles will identify policies, procedures or 
processes not previously addressed 
c. Statement 13: A cross walk of current processes in comparison to 21 CFR 820 
Quality System Regulation will assist laboratory leaders identify and understand 
pertinent gaps in the QMS 
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4. Document Control: Statement 21: Updated and accurate standard operating procedures 
serves as verification of compliance 
5. Training: Statement 8: The program includes value stream mapping to demonstrate the 
significance of hand-offs, tasks and activities and all aspects of the LDT process beginning 
with research and development and ending with diagnostic testing 
6. Document Control: Statement 23: Record retention and timely retrieval of 
documentation related to design manufacture and testing of LDTs demonstrate regulatory 
compliance 
7. Process Control: Statement 27: The consistent uninterrupted flow of material, product, 
and information between hand- off s is critical to demonstrate the user- friendliness of the 
framework   
8. Leadership: Statement 4: Establishment of an LDT quality committee to quickly 
approval changes and provide support  
9. Design Control: Statement 20: A procedure that addresses the process for identification, 
documentation and reporting of an adverse event is referred to as Medical Device 
Reporting 
LEAST important statements common to both groups 
1. Development of a QMS Framework: Statement 34: Review the pre- assessment findings 
and create a list of necessary guidance documents in need of development 
2. Process Control: Statement 27: The consistent uninterrupted flow of material, product, 
and information between hand- off s is critical to demonstrate the user- friendliness of the 
framework 
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3. Pre-assessment of Existing QMS: Statement 13:  A cross walk of current processes in 
comparison to 21 CFR 820 Quality System Regulation will assist laboratory leaders 
identify and understand pertinent gaps in the QMS 
4. Pre-assessment of Existing QMS: Statement 14: A pre- assessment of existing policies, 
procedures and processes may reveal informal processes or documents not previously 
considered compliance to regulatory requirement 
5. Leadership: Statement 4: Establishment of an LDT quality committee to quickly 
approval changes and provide support 
6. Document Control: Statement 23: Record retention and timely retrieval of 
documentation related to design, manufacture and testing of LDTs demonstrate regulatory 
compliance 
7. Training: Statement 8: The program includes value stream mapping to demonstrate the 
significance of hand-offs, tasks and activities and all aspects of the LDT process beginning 
with research and development and ending with diagnostic testing 
8. Design Control: Statement 20: A procedure that addresses the process for identification, 
documentation and reporting of an adverse event is referred to as Medical Device 
Reporting 
Strategic Factors - Respondent Feedback  
Q9, do you agree with the strategic factors identified in the proposed framework for Quality 
Management System of LDTs? If not, please suggest additional factors pertinent to develop a 
robust framework 
1. Agree, and in fact these are important 
2. I think all 12 QSES need to be applied to ANY laboratory project - particularly LDTs. 
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3. Aside from the strategic factors outlined I think it would important to get buy-in from 
leadership to allow for the time necessary for the implementation of these factors outside 
of normal work duties. In addition, each lab using these processes should have at least one 
go-to super user that can help navigate these processes. 
4. An additional factor is a defined process for management to review and re-evaluate whether 
current resources (both personnel and equipment) are sufficient to address QMS gaps, 
maintain established processes, and implement changes 
Feedback- The Establishment of a Quality Management System Framework 
Q10 - Do you think the establishment of a Quality Management System framework will assist 
LDT laboratories incorporate regulatory requirements such as design control more readily? If not, 
why and what else is necessary?  
1. A fully functional QMS is needed for a laboratory to meet accreditation requirements. 
Design and document control is paramount in having this happen.  
2. The QMS framework will not only assist LDT Lab and also assist clinical lab as well in 
compliance with regulatory requirements  
3. definitely yes and having a framework that is accepted throughout our industry will set a 
level playing 8eld as well provide structure, uniformity and integrity to the entire process  
4. Yes, it could help by providing guidance. The biggest issue with some of the most complex 
LDT's is the clinical significance, and how results derived from a LDT are being used or 
will be used to guide therapy.  
5. Yes, the QMS framework will provide these laboratories with the tools to ensure LDT 
development is conducted and documented consistently, with demonstration of regulatory 
compliance as a by-product.  
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6. Yes, a QMS is foundational to building LDTs into a lab.  
7. I do think that you could crosswalk each clause of Part 820 to the elements of each QSE 
and use the QSEs as the QMS framework for LDTs. QSE Process Management would be 
the location of all Part 820 clauses related to design. Everything else in Part 820 comes 
from ISO 9001:1994 and sorts easily to each QSE. We used ISO 9011:1994 when we 
created the QSEs in 1998. 
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APPENDIX H: DESCRIPTIVE STATEMENTS 
Descriptive statistics for all 40 statements with corresponding mean and standard deviation. 
Descriptive Statistics     
 N Minimum Maximum Mean Std. Deviation 
Q1_2 33 1 2 1.30 0.467 
Q1_5 33 1 2 1.30 0.467 
Q1_1 33 1 2 1.33 0.479 
Q1_3 33 1 2 1.48 0.508 
Q6_4 32 1 3 1.53 0.567 
Q3_5 33 1 3 1.64 0.603 
Q8_2 33 1 3 1.64 0.603 
Q5_5 32 1 3 1.66 0.602 
Q6_3 32 1 3 1.66 0.602 
Q2_5 33 1 3 1.67 0.595 
Q8_1 33 1 3 1.67 0.645 
Q4_1 33 1 4 1.67 0.692 
Q8_3 33 1 3 1.70 0.585 
Q2_2 33 1 3 1.70 0.637 
Q7_5 31 1 3 1.71 0.643 
Q7_1 32 1 3 1.72 0.581 
Q8_5 33 1 3 1.79 0.650 
Q2_4 33 1 3 1.82 0.635 
Q5_2 33 1 3 1.82 0.808 
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Q4_3 33 1 5 1.82 0.846 
Q8_4 33 1 4 1.82 0.683 
Q3_2 33 1 5 1.88 0.992 
Q4_2 33 1 4 1.88 0.781 
Q6_1 31 1 3 1.90 0.651 
Q5_4 33 1 3 1.91 0.723 
Q6_5 32 1 3 1.97 0.782 
Q7_3 32 1 4 1.97 0.740 
Q2_1 33 1 3 1.97 0.728 
Q4_4 33 1 3 1.97 0.684 
Q7_2 32 1 3 2.00 0.568 
Q5_1 33 1 5 2.00 1.000 
Q2_3 33 1 3 2.03 0.728 
Q3_1 33 1 3 2.03 0.770 
Q7_4 32 1 3 2.03 0.595 
Q3_3 33 1 5 2.06 0.827 
Q5_3 33 1 3 2.12 0.820 
Q3_4 33 1 4 2.15 0.870 
Q6_2 32 1 3 2.16 0.628 
Q1_4 33 1 5 2.24 0.969 
Q4_5 33 1 4 2.39 1.029 
Valid N (list wise) 29     
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Statement of the Problem: We explore the 2014 draft guidance by the FDA entitled Framework 
for Regulatory Oversight of Laboratory Developed Tests (LDT) extended from the medical device 
industry and discuss how these requirements may be applicable to laboratory medicine. We 
introduce terms, definitions and provide a call for action for leaders to prepare for the potential 
adherence to regulatory requirements and explore if compliance was achievable in a laboratory 
environment to design, develop and validate Laboratory Developed Tests. If not, why not, and 
what would be the limiting steps. 
Method: We perform interviews with laboratory professionals to explore their concerns and 
challenges regarding the FDA draft guidance then translate the results into strategic factors. Based 
on the feedback, we surveyed laboratory experts in the field of LDT to develop and test strategic 
factors that would comprise an effective quality management system framework (QMS) to comply 
with the FDA proposal.  We describe the methodology to translate the strategic factors into a 
design that would transform the existing laboratory structure into a regulatory quality management 
system.  
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Conclusion: Nine interviewees and 35 survey respondents shared the importance of risk 
classification, process validation, patient safety and general ambiguity for the development of 
LDT. We utilize the top supporting statements and associated factors chosen by experts as 
extremely important for LDT development as the building blocks for implementation of a 
regulatory QMS framework.  The framework includes six phases of implementation: 1) 
establishment of a leadership support structure, 2) training, 3) pre-assessment of current laboratory 
processes, 4) adoption of design control, 5) process controls, 6) process validation and the 
application of an agile Stage Gate technique for test development. 
 Respondents agree that a regulatory agile quality management system is needed in laboratories 
that develop LDT.  Utilizing the strategic factors, we develop a novel approach to LDT design, 
development and testing that extends the existing laboratory structure with a proven product 
development methodology technique called agile stage gate hybrid with the assignment of 
dedicated, accountable cross-functional teams for go/no-go approvals at every step and institute a 
coordinator position to review, document and expedite LDT development throughout the testing 
process. 
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